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ABSTRACT 
Objective: To transform heterogeneous clinical data  from electronic health records into 
clinically meaningful constructed features using data driven method that rely, in part, on 
temporal relations among data.  
Materials and Methods: The clinically meaningful representations of medical concepts 
and patients are the key for health analytic applications. Most of existing approaches 
directly construct features mapped to raw data (e.g., ICD or CPT codes), or utilize some 
ontology mapping such as SNOMED codes. However, none of the existing approaches 
leverage EHR data directly for learning such concept representation. We propose a new 
way to represent heterogeneous medical concepts (e.g., diagnoses, medications and 
procedures) based on co-occurrence patterns in longitudinal electronic health records. The 
intuition behind the method is to map medical concepts that are co-occuring closely in time 
to similar concept vectors so that their distance will be small. We also derive a simple 
method to construct patient vectors from the related medical concept vectors. 
Results: For qualitative evaluation, we study similar medical concepts across diagnosis, 
medication and procedure. In quantitative evaluation, our proposed representation 
significantly improves the predictive modeling performance for onset of heart failure (HF), 
where classification methods (e.g. logistic regression, neural network, support vector 
machine and K-nearest neighbors) achieve up to 23% improvement in area under the ROC 
curve (AUC) using this proposed representation.  
Conclusion: We proposed an effective method for patient and medical concept 
representation learning. The resulting representation can map relevant concepts together 
and also improves predictive modeling performance.  
Introduction 
Growth in use of electronic health records (EHR) in health care delivery is opening 
unprecedented opportunities to predict patient risk, understand what works best for a given 
patient, and to personalize clinical decision-making. But, raw EHR data,  represented by a 
heterogeneous mix of elements (e.g., clinical measures, diagnoses, medications, 
procedures) and voluminous unstructured content, may not be optimal for analytic uses or 
even for clinical care. While higher order clinical features (e.g., disease phenotypes) are 
intuitively more meaningful and can reduce data volume, they may fail to capture 
meaningful information inherent to patient data. We explored whether novel data driven 
methods that rely on the temporal occurrence of EHR data elements could yield higher 
order intuitively interpretable features that both capture pathophysiologic relations inherent 
to data and improve performance of predictive models.       
Growth in use of EHRs is raising fundamental questions on optimal ways to 
represent structured and unstructured data. Medical ontologies such as SNOMED, RxNorm 
and LOINC offer structured hierarchical means of compressing data and of understand 
relations among data from different domains (e.g., disease diagnosis, labs, prescriptions). 
But, these ontologies do not offer the means of extracting meaningful relations inherent to 
longitudinal patient data. Scalable methods that can detect pathophysiologic relations 
inherent to longitudinal EHR data and construct intuitive features may accelerate more 
effective use of EHR data in clinical care and advances in performance of predictive 
analytics.   
The abstract concepts inherent to existing ontologies does not provide a means to 
connect elements in different domains to a common underlying pathophysiologic 
constructs that are represented by how data elements co-occur in time. The data driven 
approach we developed logically organizes data into higher order constructs. 
Heterogeneous medical data were mapped to a low-dimensional space that accounted for  
temporal clustering of similar concepts (e.g., A1c lab test, ICD-9 code for diabetes, 
prescription for metformin). Co-occurring clusters (e.g., diabetes and peripheral 
neuropathy) were then identified and formed into higher order pathophysiologic feature 
sets organized by prevalence.   
We propose to learn such a medical concept representation on longitudinal EHR 
data based on a state-of-the-art neural network model. We also propose an efficient way to 
derive patient representation based on the medical concept representation (or medical 
concept vectors). We calculated for a set of diseases their closest diseases, medications and 
procedures to demonstrate the clinical knowledge captured by the medical concept 
representations. We use those learned representation for heart failure prediction tasks, 
where significant performance improvement up to 23% in AUC can be obtained on many 
classification models (logistic regression: AUC 0.766 to 0.791, SVM: AUC 0.736 to 0.791, 
neural network: AUC 0.779 to 0.814, KNN: AUC 0.637 to 0.785) 
BACKGROUND 
Representation Learning in Natural Language Processing 
Recently, neural network based representation learning has shown success in many 
fields such as computer vision [1] [2] [3], audio processing [4] [5] and natural language 
processing (NLP) [6] [7] [8]. We discuss representation learning in NLP, in particular, as 
our proposed method is based on Skip-gram [6] [9], a popular method for learning word 
representations. 
Mikolov et al. [6] [9] proposed Skip-gram, a simple model based on neural network 
that can learn real-valued multi-dimensional vectors that capture relations between words 
by training on massive amount of text. The trained real-valued vectors will have similar 
values for syntactically and semantically close words such as dog and cat or would and 
could, but distinct values for words that are not. Pennington et al. [10] proposed GloVe, a 
word representation algorithm based on the global co-occurrence matrix. While GloVe and 
Skip-gram essentially achieve the same goal by taking different approaches, GloVe is 
computationally faster than Skip-gram as it precomputes co-occurrence information before 
the actual learning. Skip-gram, however, requires less number of hyper-parameters to tune 
than GloVe, and generally shows better performance [11].   
As natural language text can be seen as a sequence of codes, medical records such as 
diagnoses, medications and procedures can also be seen as a sequence of codes over time. 
In this work, we propose a framework for mapping raw medical concepts (e.g., ICD9, CPT) 
into related concept vectors using Skip-gram and validating the utility of the resulting 
medical concept vectors. 
Representation Learning in the Clinical Field 
A few researchers applied representation learning in the clinical field recently. 
Minnaro-Gimenez et al. [12] learned the representations of medical terms by applying 
Skip-gram to various medical text. They collected the medical text from PubMed, Merck 
Manuals, Medscape and Wikipedia. De Vine et al. [13] learned the representations of 
UMLS concepts from free-text patient records and medical journal abstracts. The first pre-
processed the text to map the words to UMLS concepts, then applied Skip-gram to learn 
the representations of the concepts. 
More recently, Choi et al. [14] applied Skip-gram to structured dataset from a health 
insurance company, where the dataset consisted of patient visit records along with 
diagnosis codes(ICD9), lab test results(LOINC), and drug usage(NDC). Their goal, to learn 
efficient representations of medical concepts, partially overlaps with our goal. Our study 
however, is focused on learning the representations of medical concepts and using them to 
generate patient representations, apply them to a real-world prediction problem to 
demonstrate improved performance provided by the efficient representation learning. 
MATERIALS AND METHODS 
 
Figure 1. Flowchart of the proposed method 
 
In Figure 1, we give a high-level overview of the steps we take to perform HF 
prediction. In the training phase, we first train medical concept vectors from the EHR 
dataset using Skip-gram. Then, we construct patient representation using the medical 
concept vectors. The patient representation is then used to train heart failure prediction 
models using various classifiers, namely logistic regression, support vector machine 
(SVM), multi-layer perceptron with one hidden layer (MLP) and K-nearest neighbors 
classifier (KNN). In the prediction phase, we map the medical record of a patient to medical 
concept vectors and generate patient vectors by aggregating the concept vectors. Then we 
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plug the patient vectors into the trained model, which in turn will generate the risk score 
for heart failure.  
In the following sections, we will describe medical concept representation learning 
and patient representation construction in more detail. 
Medical Concept Representation Learning 
 
Figure 2. Two different representation of diagnoses. Typically, raw data dimensionality 
N(~10,000) is much larger than concept dimensionality D(50~1,000)  
Figure 2 depicts a straightforward motivation for using a better representation for 
medical concepts. Figure 2(a) shows one-hot encoding of N unique diagnoses using N-
dimensional vectors. It is easy to see that this is not an effective representation in that the 
difference between Bronchitis and Pneumonia are the same as the difference between 
Pneumonia and Obesity. Figure 2(b) shows a better representation in that Bronchitis and 
Pneumonia share similar values compared to other diagnoses. By using Skip-gram, we will 
be able to better represent not only diagnoses but also medications and procedures as multi-
dimensional real-valued vectors that will capture the latent relations between them. 
 
Bronchitis:  [1, 0, 0, 0, 0, …, 0, 0, 0] 
Pneumonia: [0, 1, 0, 0, 0, …, 0, 0, 0] 
Obesity:      [0, 0, 1, 0, 0, …, 0, 0, 0] 
 
 
 
 
Cataract:     [0, 0, 0, 0, 0, …, 0, 0, 1] 
N-dimensional vector 
N diagnoses 
Bronchitis:  [0.4, -0.2, …, 0.2] 
Pneumonia: [0.3, -0.3, …, 0.1] 
Obesity:      [-0.7, 1.4, …, 1.2] 
 
 
 
 
Cataract:     [1.2, 0.8, …, 1.5] 
D-dimensional vector 
(a) One-hot encoding for diagnoses (b) A better representation of diagnoses 
 Figure 3. Training examples and the model architecture of Skip-gram 
 
Figure 3(a) is an example of a patient medical record in a temporal order. Skip-gram 
assumes the meaning of a concept is determined by its context(or neighbors). Therefore, 
given a sequence of concepts, Skip-gram picks a target concept and tries to predict its 
neighbors, as shown by Figure 3(b). Then we slide the context window, pick the next target 
and do the same context prediction, which is shown by Figure 3(c). Since the goal of Skip-
gram is to learn the vector representation of concepts, we need to convert medical concepts 
to D-dimensional vectors, where D is a user-chosen value typically between 50 and 1000. 
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Therefore the actual prediction is conducted with vectors, as shown by Figure 3(d), where c" is the concept at the t-th timestep, 𝐯 𝑐"  the vector that represents c". The goal of Skip-
gram is to maximize the following average log probability,  1𝑇 log 𝑝 𝑐"+,|𝑐"./0,0/,,234"56 , where 
𝑝 𝑐"+,|𝑐" = 𝑒𝑥𝑝 𝐯 𝑐"+, >𝐯 𝑐"𝑒𝑥𝑝 𝐯 𝑐 >𝐯 𝑐"?@56  
where T is the length of the sequence of medical concepts, w the size of the context window, 𝑐"  the target medical concept at timestep t, 𝑐"+,  the neighboring medical concept at 
timestep t+j,	𝐯 𝑐  the vector that represents the medical concept c, N the total number of 
medical concepts. The size of the context window is typically set to 5, giving us 10 concepts 
surrounding the target concept. Note that the conditional probability is expressed as a 
softmax function. Simply put, by maximizing the softmax score of the inner product of the 
neighboring concepts, Skip-gram learns real-valued vectors that efficiently capture the 
fine-grained relations between concepts. It needs to be mentioned that our formulation of 
Skip-gram is different from the original Skip-gram. In Mikolov et al. [9], they distinguish 
the vectors for the target concept and the vectors for the neighboring concept. In our 
formulation, we force the two sets of vectors to hold the same values as suggested by [15]. 
This simpler formulation allowed faster training and impressive results.  
Patient Representation Construction 
 In this section, we describe a simple derivation of patient representation using the 
learned medical concept vectors. One of the impressive features of Skip-gram in Mikolov 
et al. [9] was that the word vectors supported syntactically and semantically meaningful 
linear operations that enabled word analogy calculations such that the resulting vector of 
King – Man + Woman is closest to Queen vector.  
We expect that the medical concept representations learned by Skip-gram will show similar 
properties so that the concept vectors will support clinically meaningful vector additions. 
Then, an efficient representation of a patient will be as simple as converting all medical 
concepts in his medical history to medical concept vectors, then summing all those vectors 
to obtain a single representation vector, as shown in Figure 4. In the experiments, we show 
examples of clinically meaningful concept vector additions.   
 
Figure 4. Patient representation construction. (a) represents a medical record of a patient 
on a timeline. (b) The medical concepts are represented as vectors using the trained medical 
concept vectors. (c) The patient is represented as a vector by summing all medical concept 
vectors.  
 
EXPERIMENTS AND RESULTS 
Population and Source of Data 
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 Data were from Sutter Palo Alto Medical Foundation (Sutter-PAMF) primary care 
patients. Sutter-PAMF is a large primary care and multispecialty group practice that has 
used an EHR for more than a decade. The study dataset was extracted with cases and 
controls identified within the interval from 05/16/2000 to 05/23/2013.  The EHR data 
included demographics, smoking and alcohol consumptions, clinical and laboratory values,  
International Classification of Disease version 9 (ICD-9) codes associated with encounters, 
order, and referrals, procedure information in Current Procedural Terminology (CPT) 
codes and medication prescription information in medical names. The dataset contained 
265,336 patients with  555,609 unique clinical events in total.   
Configuration for Medical Concept Representation Learning  
To apply Skip-gram, we scanned through encounter, medication order, procedure 
order and problem list records of all 265,336 patients, and extracted diagnosis, medication 
and procedure codes assigned to each patient in temporal order. If a patient received 
multiple diagnoses, medications or procedures at a single visit, then those medical codes 
were given the same timestamp. The respective number of unique diagnoses, medications 
and procedures was 11,460, 17,769 and 9,370 totaling to 38,599 unique medical concepts. 
We used 100-dimensional vectors to represent medical concepts(i.e. D=100 in Figure 2(b)), 
considering 300 was sufficient to effectively represent 692,000 vocabularies in NLP. [9] 
 We used Theano [16], a Python library for evaluating mathematical expression to 
implement Skip-gram. Theano can also take advantage of GPUs to greatly improve the 
speed of calculations involving large matrices. For optimization, we used Adadelta [17], 
which employs adaptive learning rate. Unlike stochastic gradient descent (SGD), which is 
widely used for training neural networks, Adadelta does not depend very strongly on the 
setting of the learning rate, and shows good performance. Using Theano 0.7 and CUDA 7 
on an Ubuntu machine with Xeon E5-2697 and Nvidia Tesla K80, it took approximately 
43 hours to run 10 epochs of Adadelta with the batch size of 100.  
Evaluation of Medical Concept Representation Learning 
 
Figure 5. Diagnosis vectors projected to a 2D space by t-SNE 
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Figure 5 shows the trained diagnosis vectors plotted in a 2D space, where we used 
t-SNE [18] to reduce the dimensions from 100 to 2. t-SNE is a dimensionality reduction 
algorithm that was specifically developed for plotting high-dimensional data into a two or 
three dimensional space. We randomly chose 1,000 diagnoses from 10 uppermost 
categories of ICD-9, which are displayed at the top of the figure. It is readily visible that 
diagnoses are generally well grouped by their corresponding categories. However, if 
diagnoses from the same category are in fact quite different, they should be apart. This is 
shown by the red box and the blue box in Figure 5. Even though they are from the same 
neoplasms category, red box indicates a group of malignant skin neoplasms (172.X, 173.X) 
while blue box indicates a group of benign skin neoplasms (216.X). Detailed figure of the 
red and blue boxes are in the supplementary section. What is more, as the black box shows, 
diagnoses from different groups are located close to one another if they are actually related. 
In the black box, iridocyclitis and eye infections related to herpes zoster are closely located, 
which corresponds to the fact that approximately 43% herpes zoster ophthalmicus (HZO) 
patients develop iridocyclitis. [19] 
In order to see how well the representation learning captured the relations between 
medications and procedures as well as diagnoses, we conduct the following study. We 
chose 100 diagnoses that occurred most frequently in the data, obtained for each diagnosis 
50 closest vectors in terms of cosine similarity, picked 5 diagnosis, medication and 
procedure vectors among the 50 vectors. Table 2 depicts a portion of the entire lis. Note 
that some cells contain less than 5 items, which is because there was less than 5 items in 
the 50 closest vectors. The entire list is provided in the supplementary section.  
 
 Table 1. Examples of diagnoses and their closest medical concepts.  
 Diagnoses Medications Procedures 
Acute upper 
respiratory 
infections  
(465.9) 
-Bronchitis, not specified as acute or chronic 
(490) 
-Cough (786.2) 
-Acute sinusitis, unspecified (461.9) 
-Acute bronchitis (466.0) 
-Acute pharyngitis (462) 
-Azithromycin 250 mg po tabs 
-Promethazine-Codeine 6.25-10 
mg/5ml po syrp 
-Amoxicillin 500 mg po caps 
-Fluticasone Propionate 50 mcg/act 
na susp 
-Flonase 50 mcg/act na susp  
-Pulse oximetry single 
-Serv prov during reg sched 
eve/wkend/hol hrs 
-Chest PA & lateral 
-Gyn cytology (pap) pa 
-Influenza vac (flu clinic 
only) 3+yo pa 
Diabetes 
mellitus  
(250.02) 
-Diabetes mellitus (250.00) 
-Mixed hyperlipidemia (272.2) 
-Other abnormal glucose (790.29) 
-Obesity, unspecified (278.00) 
-Pure hypercholesterolemia (272.0) 
-Metformin hcl 500 mg po tabs 
-Metformin hcl 1000 mg po tabs 
-Glucose blood vi strp 
-Lisinopril 10 mg po tabs 
-Lisinopril 20 mg po tabs 
-Diabetic eye exam (no bill) 
-Diabetes education, int 
-Ophthalmology, int 
-Diabetic foot exam (no bill) 
-Influenza vac 3+yr (v04.81) 
im 
Edema 
(782.3) 
-Anemia, unspecified (285.9) 
-Congestive heart failure, unspecified (428.0) 
-Unspecified essential hypertension (401.9) 
-Atrial fibrillation (427.31) 
-Chronic kidney disease, Stage III (moderate) 
(585.3) 
-Furosemide 20 mg po tabs 
-Hydrochlorothiazide 25 mg po tabs 
-Hydrocodone-Acetaminophen 5-500 
mg po tabs 
-Cephalexin 500 mg po caps 
-Furosemide 40 mg po tabs 
-Debridement of nails, 6 or 
more 
-OV est pt min serv 
-EKG 
-ECG and interpretation 
-Chest PA & lateral 
Tear film 
insufficiency, 
unspecified 
(375.15) 
-Blepharitis, unspecified (373.00) 
-Senile cataract, unspecified (366.10) 
-Presbyopia (367.4) 
-Preglaucoma, unspecified (365.00) 
-Other chronic allergic conjunctivitis 
(372.14) 
-Glasses 
-Erythromycin 5 mg/gm op oint 
-Patanol 0.1 % op soln 
-Refraction 
-Visual field exam extended 
-Visual field exam limited 
-Referral to ophthalmology, 
int 
-Ophthalmology, int 
Benign 
essential 
hypertension 
(401.1) 
-Hyperlipidemia (272.4) 
-Essential hypertension (401.9) 
-Pure hypercholesterolemia (272.0) 
-Mixed hyperlipidemia (272.2) 
-Diabetes mellitus (250.00) 
-Hydrochlorothiazide 25 mg po tabs 
-Atenonol 50 mg po tabs 
-Lisinopril 10 mg po tabs 
-Lisinopril 40 mg po tabs 
-Lisinopril 20 mg po tabs 
-ECG and interpretation 
-Influenza vac 3+yr im 
-Immun admin im/sq/id/perc 
1st vac only 
-GI, int 
-OV est pt lev 3 
 
 
 
 
 
 
Evaluation of Medical Concept Vector Additions 
Table 2. Vector operations of medical vectors trained by Skip-gram.  
 Diagnoses Medications Procedures 
Hypertension (401.9) 
+ 
Obesity (278.0) 
-Hyperlipidemia (272.4) 
-Diabetes (250.00) 
-Coronary atherosclerosis (414.00) 
-Hypertension (401.1) 
-Chronic kidney disease (585.3) 
-Hydrochlorothiazide 
-Valsartan 
-Nifedipine 
-Lisinopril 
-Losartan potassium 
N/A 
Fever (780.60) 
+ 
Cough (786.2) 
-Pneumonia (486) 
-Acute bronchitis (466.0) 
-Acute upper respiratory infections 
(465.9) 
-Bronchitis (490) 
-Acute sinusitis (461.9) 
-Azithromycin 
-Promethazine-codeine 
-Guaifenesin-codeine 
-Proair HFA 
-Levofloxacin 
-X-ray chest 
-Chest PA & Lateral 
-Pulse oximetry 
-Serv prov during reg sched 
eve/wkend/hol hrs 
-Inhalation Rx for 
obstruction MDI/NEB 
Visual Disturbance (368.8) 
+ 
Pain in/around Eye (379.91) 
-Tear film insufficiency (375.15) 
-Visual discomfort (368.13) 
-Regular astigmatism (367.21) 
-Presbyopia (367.4) 
-Blepharitis (373.00) 
-Glasses 
-Erythromycin ointment 
-Patanol 
-Ophthalmology 
-Peripheral refraction 
-Referral to ophthalmology 
-Visual field exam 
-Diabetic eye exam 
Loss of Weight (783.21) 
+ 
Anxiety State (300.00) 
-Depressive disorder (311) 
-Malais & fatigue (780.79) 
-Insomnia (780.52) 
-Generalized anxiety disorder (300.02) 
-Esophageal reflux (530.81) 
-Lorazepam 
-Zolpidem tartrate 
-Omeprazole 
-Alprazolam 
-Trazodone HCL 
-Referral to GI 
-ECG & Interpretation 
-GI 
-EKG 
-Chest PA & Lateral 
Hallucination (780.1) 
+ 
Speech Disturbance (784.59) 
-Dysarthria (784.51) 
-Secondary parkinsonism (332.1) 
-Senile dementia with delirium (290.3) 
-Mental disorder (294.9) 
-Paranoid state (297.9) 
-Midorine HCL 
-Risperdal 
-Rivastigmine Tartrate 
-Rivastigmine 
-Referral to geriatrics 
-Mental status exam 
-Referral to 
neuropsychology 
-Referral to speech therapy 
Home visit est pt lev 2 
 
Due to the difficulty of generating medically interesting examples, we chose 5 
intuitive examples as shown by the first column of Table 3 to give a simple demonstration 
of the medical concept vector additions. We again generated 50 closest vectors to the sum 
of two medical concept vectors and picked 5 from each diagnosis, medication and 
procedure category.  
Setup for Heart Failure Prediction Evaluation 
In this section, we first describe why we chose heart failure (HF) prediction task as an 
application. Then we briefly mention the models to use, followed by the description of the 
data processing steps to create the training data for all models. Lastly, the evaluation 
strategy will be followed by implementation details. 
Heart failure prediction task: Onset of HF is associated with a high level of disability, 
health care costs and mortality (roughly ~50% risk of mortality within 5 years of diagnosis). 
[20] [21] There has been relatively little progress in slowing the progression of HF severity, 
largely because it is difficult to detect before actual diagnosis. As a consequence, 
intervention has primarily been confined to the time period after diagnosis, with little or no 
impact on disease progression. Earlier detection of HF could lead to improved outcomes 
through patient engagement and more assertive treatment with angiotensin converting 
enzyme (ACE)-inhibitors or Angiotensin II receptor blockers (ARBs), mild exercise, and 
reduced salt intake, and possibly other options [22] [23] [24] [25]. 
Models for performance comparison: We aim to emphasize the effectiveness of the 
medical concept representation and the patient representation derived from it. Therefore 
we trained four popular classifiers, namely logistic regression, MLP, SVM, and KNN using 
both one-hot vectors and medical concept vectors.  
Definition of Cases and Controls: Criteria for incident onset of HF, are described in [26] 
and were adopted from [27]. The criteria are defined as: 1) Qualifying ICD-9 codes for HF 
appeared as a diagnosis code in either the encounter, the problem list, or the medication 
order fields. Qualifying ICD-9 codes are listed in the supplementary section. Qualifying 
ICD-9 codes with image and other related orders were excluded because these orders often 
represent a suspicion of HF, where the results are often negative; 2) a minimum of three 
clinical encounters with qualifying ICD-9 codes had to occur within 12 months of each 
other, where the date of diagnosis was assigned to the earliest of the three dates.  If the time 
span between the first and second appearances of the HF diagnostic code was greater than 
12 months, the date of the second encounter was used as the first qualifying encounter; 3) 
ages 50 or greater to less than 85 at the time of HF diagnosis.  
Up to ten (nine on average) eligible primary care clinic-, sex-, and age-matched (in 
5-year age intervals) controls were selected for each incident HF case. Primary care 
patients were eligible as controls if they had no HF diagnosis in the 12-month period before 
diagnosis of the incident HF case. Control subjects were required to have their first office 
encounter within one year of the matching HF case patient’s first office visit, and have at 
least one office encounter 30 days before or any time after the case’s HF diagnosis date to 
ensure similar duration of observations among cases and controls.  
From 265,336 Sutter-PAMF patients, 3,884 incident HF cases and 28,903 control 
patients were identified. 
Data processing: To train the four models, we generated the dataset again from the 
encounter, medication order, procedure order and problem list records of 3,884 cases and 
28,903 controls. Based on the HF diagnosis date (HFDx) of each patient, we extracted all 
records from the 18-month period before the HFDx. To train the models with medical 
concept vectors, we converted the medical records to patient vectors as shown in Figure 4. 
To train the models with one-hot encoding, we converted the medical records to aggregated 
one-hot vectors in the same fashion as Figure 4, using one-hot vectors instead of medical 
concept vectors.  
In order to study the relation between the medical concept vectors trained with 
different sizes of data and their influence on the models’ prediction performance, we used 
three kinds of medical concept vectors: 1) The one trained with only HF cases (3,884 
patients), 2) The one trained with HF cases and controls (32,787 patients), 3) The one 
trained with the full sample (265,336 patients). Note that medical concept vectors trained 
with smaller number of patients cover less number of medical concepts. Therefore, when 
converting patient records to patient vectors as Figure 4, we excluded all medical codes 
that did not have matching medical concept vectors. All input vectors were normalized to 
zero mean and unit variance.  
Evaluation strategy: We used six-fold cross validation to train and evaluate all models, 
and to estimate how well the models will generalize to independent datasets. Prediction 
performance was measured using area under the ROC curve (AUC), on data not used in 
the training. We used the confidence score to calculate its AUC for SVM. Detailed 
explanation of the cross validation is given in the supplementary section. 
Implementation details: Logistic regression and MLP were implemented with Theano 
and trained with Adadelta. SVM and KNN were implemented with Python Scikit-Learn. 
All models were trained by the same machine used for medical concept representation 
learning. Hyper-parameters used for training each model are described in the 
supplementary section. 
Evaluation of Heart Failure Prediction 
 Figure 6. Heart failure prediction performance of various models and input vectors.  
 
Figure 6 shows the average AUC of 6-fold cross validations of various models and 
input vectors. The colors represent different training input vectors. The error bars indicate 
the standard deviation derived from the 6-fold cross evaluation. The power of medical 
concept representation learning is evident as all models show significant improvement in 
the HF prediction performance. Logistic regression and SVM, both being linear models, 
show similar performance when trained with medical concept vectors, although SVM 
benefits slightly more from using the better representation of medical concepts. MLP also 
benefits from using medical concept vectors, and, being a non-linear model, shows better 
performance compared to logistic regression and SVM. It is interesting that KNN benefits 
the most from using the medical concept vectors, even the ones trained on the smallest 
0.5 
0.55 
0.6 
0.65 
0.7 
0.75 
0.8 
0.85 
0.9 
0.95 
1 
Logistic Regression SVM MLP KNN 
A
U
C
 
One-hot encoding Medical concept vectors trained on 4K patients 
Medical concept vectors trained on 33K patients Medical concept vecotrs trained on 265K patients 
dataset. Considering the fact that KNN classification is based on the distances between data 
points, this is a clear indication that proper medical concept representation can alleviate the 
sparsity problem induced by the simple one-hot encoding.  
Figure 6 also tells us that medical concept representation is best learned with a large 
dataset as shown by Mikolov et al. [6] However, in most models, especially KNN, even 
the medical concept vectors trained with the smallest number of patients improves the 
prediction performance. It is quite surprising given the fact that we used less amount of 
information by excluding unmatched medical codes when using medical concept vectors 
trained with a small number of patients, the models still show better prediction performance. 
This again is a clear proof that medical concept representation learning provides more 
effective way to represent medical concepts than one-hot encoding. 
 
Table 3. Training speed improvement. (*Since KNN does not require training, we display 
classification time instead) 
 Logistic regression SVM MLP KNN* 
One-hot 
encoding 81.3 20.5 85.7 2900.82 
Medical 
concept vectors 5.3 1.9 5.6 36.66 
Speed -up x15.3 x10.8 x15.3 x79.1 
 
Table 4 depicts the training time for each model when using one-hot encoding and 
medical concept vectors. Considering the high-dimensionality of one-hot encoding, 
training the models with medical concept vectors should provide significant speed-up, as 
shown by the last row of Table 4. This shows that medical concept vectors not only improve 
performance, but also significantly reduce the training time. 
 Before discussing future work, we would like to emphasize the fact that our entire 
experiments were conducted completely without expert knowledge such as medical 
ontologies or features designed by medical experts. Using only the medical order records, 
we were able to produce clinically meaningful representation of medical concepts. This is 
an inspiring discovery that can be extended for numerous other medical problems.  
Future Work 
 Although medical concept vectors have shown impressive results, it would be even 
more effective if deeper medical information could be embedded such as lab results or 
patient demographic information. This would enable us to represent the medical state of 
patients more accurately. 
 Using expert knowledge is another thing we should try. Even though we have 
shown impressive performance only by using medical records, this does not mean we 
cannot benefit from well-established expert medical knowledge, such as specific features 
or medical ontologies.  
 Another natural extension of our work is to address other medical problems. 
Although this work focused on the early detection of heart failure, our approach is very 
general that it could be applied to any kind of disease prediction problem. And the medical 
concept vectors can also be used in numerous medical applications as well. 
CONCLUSION 
 We proposed a new way of representing heterogeneous medical concepts as real-
valued vectors and constructing efficient patient representation using the state-of-the-art 
Deep Learning method. We have qualitatively shown that the trained medical concept 
vectors indeed captured medical insights compatible with our medical knowledge and 
experience. For the heart failure prediction task, medical concept vectors improved the 
performance of many classifiers, thus quantitatively proving its effectiveness. We 
discussed the limitation of our method and possible future works, which include deeper 
utilization of medical information, combining expert knowledge into our framework, and 
expanding our approach to various medical applications.   
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SUPPLEMENTARY 
Table 4. Qualifying ICD-9 codes for heart failure 
ICD-9 
Code Description 
398.91 Rheumatic heart failure (congestive) 
402.01 Malignant hypertensive heart disease with heart failure 
402.11 Benign hypertensive heart disease with heart failure 
402.91 Unspecified hypertensive heart disease with heart failure 
404.01 Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified 
404.03 Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease 
404.11 Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified 
404.13 Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease 
404.91 Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified 
404.93 Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease 
428.0 Congestive heart failure, unspecified 
428.1 Left heart failure 
428.20 Systolic heart failure, unspecified 
428.21 Acute systolic heart failure 
428.22 Chronic systolic heart failure 
428.23 Acute on chronic systolic heart failure 
428.30 Diastolic heart failure, unspecified 
428.31 Acute diastolic heart failure 
428.32 Chronic diastolic heart failure 
428.33 Acute on chronic diastolic heart failure 
428.40 Combined systolic and diastolic heart failure, unspecified 
428.41 Acute combined systolic and diastolic heart failure 
428.42 Chronic combined systolic and diastolic heart failure 
428.43 Acute on chronic combined systolic and diastolic heart failure 
428.9 Heart failure, unspecified 
 
 
 
 
 
 
 
 Red and Blue Box of Figure 5 
 
Figure 7. Detailed version of the red box of Figure 5 
 
Table 5. List of ICD-9 codes that appear in Figure 7, and their descriptions 
ICD-9 Code Description 
172.3 Malignant melanoma of skin of other and unspecified parts of face 
172.4 Malignant melanoma of skin of scalp and neck 
172.5 Malignant melanoma of skin of trunk, except scrotum 
173.0 Other and unspecified malignant neoplasm of skin of lip 
173.1 Other and unspecified malignant neoplasm of skin of eyelid, including canthus 
173.2 Other and unspecified malignant neoplasm of skin of ear and external auditory canal 
173.3 Other and unspecified malignant neoplasm of skin of other and unspecified parts of face 
173.31 Basal cell carcinoma of skin of other and unspecified parts of face 
173.4 Other and unspecified malignant neoplasm of scalp and skin of neck 
173.41 Basal cell carcinoma of scalp and skin of neck 
173.5 Other and unspecified malignant neoplasm of skin of trunk, except scrotum 
173.50 Unspecified malignant neoplasm of skin of trunk, except scrotum 
173.51 Basal cell carcinoma of skin of trunk, except scrotum 
173.6 Other and unspecified malignant neoplasm of skin of upper limb, including shoulder 
173.7 Other and unspecified malignant neoplasm of skin of lower limb, including hip 
173.71 Basal cell carcinoma of skin of lower limb, including hip 
173.9 Other and unspecified malignant neoplasm of skin, site unspecified 
173.91 Basal cell carcinoma of skin, site unspecified 
173.6 
173.4 
173.7 
173.5 
173.9 
173.3 
173.1 
173.2 
173.0 
172.3 
172.4 
238.9 
173.91 
173.50 
173.71 
172.5 
173.51 
173.41 
173.31 
238.9 Neoplasm of uncertain behavior, site unspecified 
 
 
Figure 8. Detailed version of the blue box of Figure 5 
 
Table 6. List of ICD-9 codes that appear in Figure 8, and their descriptions 
ICD-9 Code Description 
078.10 Viral warts, unspecified 
216.3 Benign neoplasm of skin of other and unspecified parts of face 
216.5 Benign neoplasm of skin of trunk, except scrotum 
216.6 Benign neoplasm of skin of upper limb, including shoulder 
216.7 Benign neoplasm of skin of lower limb, including hip 
216.8 Benign neoplasm of other specified sites of skin 
216.9 Benign neoplasm of skin, site unspecified 
228.00 Hemangioma of unspecified site 
238.2 Neoplasm of uncertain behavior of skin 
448.1 Nevus, non-neoplastic 
448.9 Other and unspecified capillary diseases 
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6-fold Cross Validation Scheme 
 
 
Figure 9. Diagram of 6-fold cross validation 
 
 Figure 6 depicts the 6-fold cross validation we performed for HF prediction. As 
explained earlier, the entire cohort is divided into 7 chunks, and two chunks take turn to 
play as the validation set and the test set.  
 
 
 
 
Training Set 
Validation Set 
Test Set 
Fold 1 
Fold 2 
Fold 6 
32,787 Patients 
  
Hyper-parameters used for training models 
After experimenting with various values, the following hyper-parameter setting produced 
the best performance. We used Theano 0.7 and CUDA 7 for training logistic regression, 
MLP, and GRU models. SVM was implemented with Scikit-Learn Linear SVC. KNN was 
implemented with Scikit-Learn KNeighborsClassifier. 
 
Table 7. Hyper-parameter settings for training the models 
Model Hyper-parameter 
Logistic regression,  
one-hot vectors L2 regularization: 0.1, Max epoch: 100 
Logistic regression,  
medical concept vectors L2 regularization: 0.01, Max epoch: 100 
SVM, 
one-hot vectors L2 regularization: 0.000001, Dual: False 
SVM, 
medical concept vectors L2 regularization: 0.001, Dual: False 
MLP, 
one-hot vectors L2 regularization: 0.01, Hidden layer size: 15, Max epoch: 100 
MLP, 
medical concept vectors L2 regularization: 0.001, Hidden layer size: 100, Max epoch: 100 
KNN, 
one-hot vectors Number of neighbors: 15 
KNN, 
medical concept vectors Number of neighbors: 100 
 
 
 
 
 
 
 
 Complete table of 100 frequent diagnoses and their closest diagnoses, medications and 
procedures 
 Diagnoses Medications Procedures 
Myalgia and myositis, 
unspecified (729.1) 
-Lumbago (724.2) 
-Thoracic or lumbosacral 
neuritis or radiculitis, 
unspecified (724.4) 
-Degeneration of lumbar or 
lumbosacral intervertebral 
disc (722.52) 
-Other malaise and fatigue 
(780.79) 
-HYDROCODONE-
ACETAMINOPHEN 5-500 MG 
PO TABS 
-ZOLPIDEM TARTRATE 10 
MG PO TABS 
-CYCLOBENZAPRINE HCL 
10 MG PO TABS 
-HYDROCODONE-
ACETAMINOPHEN 10-325 
MG PO TABS 
-TRAMADOL HCL 50 MG PO 
TABS 
-PR INJ TRIGGER POINT(S) 
1 OR 2 MUSCLES 
-PHYSICAL MEDICINE, INT 
-TRIAMCINOLONE 
ACETONIDE *KENALOG 
INJ 
-ASP/INJ MAJOR 
JOINT/BURS/CYST 
-PR METHLYPRED ACET 
(BU 21 - 40MG) *DEPO-
MEDROL INJ 
Pain in limb (729.5) -Keratoderma, acquired 
(701.1) 
-Plantar fascial 
fibromatosis (728.71) 
-Other specified diseases of 
nail (703.8) 
-Disturbance of skin 
sensation (782.0) 
-HYDROCODONE-
ACETAMINOPHEN 5-500 MG 
PO TABS 
-DEBRIDEMENT OF NAILS, 
6 OR MORE 
-PODIATRY, INT 
-REFERRAL TO PODIATRIC 
MEDICINE/SURGERY, INT 
-PR OV EST PT LEV 3 
-FOOT COMPLETE 
Tear film insufficiency, 
unspecified (375.15) 
-Senile cataract, 
unspecified (366.10) 
-Presbyopia (367.4) 
-Preglaucoma, unspecified 
(365.00) 
-Other chronic allergic 
conjunctivitis (372.14) 
-GLASSES 
-ERYTHROMYCIN 5 MG/GM 
OP OINT 
-PATANOL 0.1 % OP SOLN 
-PR REFRACTION 
-PR VISUAL FIELD EXAM 
EXTENDED 
-PR VISUAL FIELD EXAM 
LIMITED 
-REFERRAL TO 
OPHTHALMOLOGY, INT 
-OPHTHALMOLOGY, INT 
Headache (784.0) -Dizziness and giddiness 
(780.4) 
-Cervicalgia (723.1) 
-Other malaise and fatigue 
(780.79) 
-Acute sinusitis, 
unspecified (461.9) 
-HYDROCODONE-
ACETAMINOPHEN 5-500 MG 
PO TABS 
-FLUTICASONE 
PROPIONATE 50 MCG/ACT 
NA SUSP 
-CYCLOBENZAPRINE HCL 
10 MG PO TABS 
-FLONASE 50 MCG/ACT NA 
SUSP 
-AZITHROMYCIN 250 MG PO 
TABS 
-REFERRAL TO 
NEUROLOGY, INT 
-NEUROLOGY, INT 
-SERV PROV DURING REG 
SCHED EVE/WKEND/HOL 
HRS 
-PR OV EST PT LEV 3 
-PR ECG AND 
INTERPRETATION 
Disturbance of skin 
sensation (782.0) 
-Brachial neuritis or 
radiculitis NOS (723.4) 
-Cervicalgia (723.1) 
-Pain in limb (729.5) 
-Headache (784.0) 
-HYDROCODONE-
ACETAMINOPHEN 5-500 MG 
PO TABS 
-PREDNISONE 20 MG PO 
TABS 
-NEUROLOGY, INT 
-SENSE/MIXED N 
CONDUCTION TST 
-REFERRAL TO 
NEUROLOGY, INT 
-PR NERVE COND STUDY 
MOTOR W F-WAVE EA 
-PR EMG NEEDLE ONE 
EXTREMITY 
Edema (782.3) -Congestive heart failure, 
unspecified (428.0) 
-Unspecified essential 
hypertension (401.9) 
-Atrial fibrillation (427.31) 
-Chronic kidney disease, 
Stage III (moderate) 
(585.3) 
-FUROSEMIDE 20 MG PO 
TABS 
-HYDROCHLOROTHIAZIDE 
25 MG PO TABS 
-HYDROCODONE-
ACETAMINOPHEN 5-500 MG 
PO TABS 
-CEPHALEXIN 500 MG PO 
CAPS 
-DEBRIDEMENT OF NAILS, 
6 OR MORE 
-PR OV EST PT MIN SERV 
-EKG 
-PR ECG AND 
INTERPRETATION 
-CHEST PA & LATERAL 
-FUROSEMIDE 40 MG PO 
TABS 
Asthma, unspecified type, 
unspecified (493.90) 
-Allergic rhinitis, cause 
unspecified (477.9) 
-Acute bronchitis (466.0) 
-Bronchitis, not specified as 
acute or chronic (490) 
-Acute upper respiratory 
infections of unspecified 
site (465.9) 
-AZITHROMYCIN 250 MG PO 
TABS 
-ALBUTEROL SULFATE HFA 
108 (90 BASE) MCG/ACT IN 
AERS 
-ALBUTEROL SULFATE HFA 
108 MCG/ACT IN AERS 
-PROMETHAZINE-CODEINE 
6.25-10 MG/5ML PO SYRP 
-ALBUTEROL 90 MCG/ACT 
IN AERS 
-CHEST PA & LATERAL 
-PULSE OXIMETRY SINGLE 
-PR INHALATION RX FOR 
OBSTRUCTION MDI/NEB 
-XR CHEST 2 VIEWS PA 
LATERAL 
-IMMUN ADMIN 
IM/SQ/ID/PERC 1ST VAC 
ONLY 
Routine gynecological 
examination (V72.31) 
-Other screening 
mammogram (V76.12) 
-Screening for lipoid 
disorders (V77.91) 
-Routine general medical 
examination at a health care 
facility (V70.0) 
-Screening for unspecified 
condition (V82.9) 
-OBTAINING SCREEN PAP 
SMEAR 
-GYN CYTOLOGY (PAP) PA 
-MAMMOGRAM SCREENING 
-MAMMO SCREENING 
BILATERAL DIGITAL 
-SCRN MAMMO DIR DIG 
IMAGE BIL (V76.12) 
  
Diabetes mellitus without 
mention of complication, 
type II or unspecified type, 
uncontrolled (250.02) 
-Mixed hyperlipidemia 
(272.2) 
-Other abnormal glucose 
(790.29) 
-Obesity, unspecified 
(278.00) 
-Pure hypercholesterolemia 
(272.0) 
-METFORMIN HCL 500 MG 
PO TABS 
-METFORMIN HCL 1000 MG 
PO TABS 
-GLUCOSE BLOOD VI STRP 
-LISINOPRIL 10 MG PO TABS 
-LISINOPRIL 20 MG PO TABS 
-DIABETIC EYE EXAM (NO 
BILL) 
-DIABETES EDUCATION, 
INT 
-OPHTHALMOLOGY, INT 
-DIABETIC FOOT EXAM 
(NO BILL) 
-INFLUENZA VAC 3+YR 
(V04.81) IM 
Need for prophylactic 
vaccination and inoculation 
against diphtheria-tetanus-
pertussis, combined [DTP] 
[DTaP] (V06.1) 
-Laboratory examination 
ordered as part of a routine 
general medical 
examination (V72.62) 
-Need for prophylactic 
vaccination and inoculation 
against other combinations 
of diseases (V06.8) 
-Screening for lipoid 
disorders (V77.91) 
-Need for prophylactic 
vaccination and inoculation 
against influenza (V04.81) 
-FLUTICASONE 
PROPIONATE 50 MCG/ACT 
NA SUSP 
-AZITHROMYCIN 250 MG PO 
TABS 
-ZOLPIDEM TARTRATE 10 
MG PO TABS 
-SIMVASTATIN 20 MG PO 
TABS 
-TDAP VAC 11-64 YO 
*ADACEL (V06.8) IM 
-MAMMO SCREENING 
BILATERAL DIGITAL 
-PR INFLUENZA VACC 
PRES FREE 3+ YO 0.5ML IM 
-REFERRAL TO GI, INT 
-PNEUMOCOCCAL VAC 
(V03.82) IM/SQ 
Diabetes mellitus without 
mention of complication, 
type II or unspecified type, 
not stated as uncontrolled 
(250.00) 
-Unspecified essential 
hypertension (401.9) 
-Diabetes mellitus without 
mention of complication, 
type II or unspecified type, 
uncontrolled (250.02) 
-Obesity, unspecified 
(278.00) 
-Benign essential 
hypertension (401.1) 
-METFORMIN HCL 500 MG 
PO TABS 
-METFORMIN HCL 1000 MG 
PO TABS 
-GLUCOSE BLOOD VI STRP 
-HYDROCHLOROTHIAZIDE 
25 MG PO TABS 
-LISINOPRIL 10 MG PO TABS 
-DIABETIC EYE EXAM (NO 
BILL) 
-PR DIABETIC EYE EXAM 
(NO BILL) 
-INFLUENZA VAC 3+YR 
(V04.81) IM 
-IMMUN ADMIN 
IM/SQ/ID/PERC 1ST VAC 
ONLY 
-OPHTHALMOLOGY, INT 
Personal history of colonic 
polyps (V12.72) 
-Special screening for 
malignant neoplasms of 
colon (V76.51) 
-Family history of 
malignant neoplasm of 
gastrointestinal tract 
(V16.0) 
-Diverticulosis of colon 
(without mention of 
hemorrhage) (562.10) 
-Routine general medical 
examination at a health care 
facility (V70.0) 
-PEG-KCL-NACL-NASULF-
NA ASC-C 100 G PO SOLR 
-MOVIPREP 100 G PO SOLR 
-SIMVASTATIN 20 MG PO 
TABS 
-OMEPRAZOLE 20 MG PO 
CPDR 
-PR COLONOSCOPY 
W/BIOPSY(S) 
-PR COLONOSCOPY 
W/RMVL 
LESN/TUM/POLYP SNARE 
-REFERRAL TO GI, INT 
-GI, INT 
-PR COLONOSCOPY DIAG 
Acute upper respiratory 
infections of unspecified 
site (465.9) 
-Cough (786.2) 
-Acute sinusitis, 
unspecified (461.9) 
-Acute bronchitis (466.0) 
-Acute pharyngitis (462) 
-AZITHROMYCIN 250 MG PO 
TABS 
-PROMETHAZINE-CODEINE 
6.25-10 MG/5ML PO SYRP 
-AMOXICILLIN 500 MG PO 
CAPS 
-FLUTICASONE 
PROPIONATE 50 MCG/ACT 
NA SUSP 
-FLONASE 50 MCG/ACT NA 
SUSP 
-PULSE OXIMETRY SINGLE 
-SERV PROV DURING REG 
SCHED EVE/WKEND/HOL 
HRS 
-CHEST PA & LATERAL 
-GYN CYTOLOGY (PAP) PA 
-INFLUENZA VAC (FLU 
CLINIC ONLY) 3+YO PA 
Need for prophylactic 
vaccination and inoculation 
against tetanus-diphtheria 
[Td] (DT) (V06.5) 
-Routine general medical 
examination at a health care 
facility (V70.0) 
-Other general medical 
examination for 
administrative purposes 
(V70.3) 
-Need for prophylactic 
vaccination and inoculation 
against other combinations 
of diseases (V06.8) 
-Multiphasic screening 
(V82.6) 
-TD VAC 7+ YO (V06.5) IM 
-IMMUN ADMIN 
IM/SQ/ID/PERC 1ST VAC 
ONLY 
-CHART ABSTRACTION 
SIMP (V70.3) 
-MAMMOGRAM SCREENING 
-IMMUN ADMIN, EACH ADD 
  
Esophageal reflux (530.81) -Unspecified essential 
hypertension (401.9) 
-Allergic rhinitis, cause 
unspecified (477.9) 
-Cough (786.2) 
-Routine general medical 
examination at a health care 
facility (V70.0) 
-OMEPRAZOLE 20 MG PO 
CPDR 
-ACIPHEX 20 MG PO TBEC 
-PROTONIX 40 MG PO TBEC 
-PRILOSEC 20 MG PO CPDR 
-FLUTICASONE 
PROPIONATE 50 MCG/ACT 
NA SUSP 
-GI, INT 
-PR ECG AND 
INTERPRETATION 
-PR LARYNGOSCOPY FLEX 
DIAG 
-PR OV EST PT LEV 3 
-CHEST PA & LATERAL 
Other specified aftercare 
following surgery (V58.49) 
-Lens replaced by other 
means (V43.1) 
-Senile cataract, 
unspecified (366.10) 
-Unspecified aftercare 
(V58.9) 
-Follow-up examination, 
following surgery, 
unspecified (V67.00) 
-GLASSES 
-HYDROCODONE-
ACETAMINOPHEN 5-500 MG 
PO TABS 
-VICODIN 5-500 MG PO TABS 
-CEPHALEXIN 500 MG PO 
CAPS 
-IBUPROFEN 600 MG PO 
TABS 
-PR ECG AND 
INTERPRETATION 
-PR OPHTHALMIC 
BIOMETRY 
-FOOT COMPLETE 
-EKG 
-PR REFRACTION 
Diarrhea (787.91) -Irritable bowel syndrome 
(564.1) 
-Nausea with vomiting 
(787.01) 
-Hemorrhage of rectum and 
anus (569.3) 
-Nausea alone (787.02) 
-METRONIDAZOLE 500 MG 
PO TABS 
-CIPRO 500 MG PO TABS 
-OMEPRAZOLE 20 MG PO 
CPDR 
-CIPROFLOXACIN HCL 500 
MG PO TABS 
-PROMETHAZINE HCL 25 
MG PO TABS 
-GI, INT 
-REFERRAL TO GI, INT 
-SERV PROV DURING REG 
SCHED EVE/WKEND/HOL 
HRS 
-PR COLONOSCOPY 
W/BIOPSY(S) 
-US ABDOMEN COMPLETE 
Coronary atherosclerosis of 
unspecified type of vessel, 
native or graft (414.00) 
-Unspecified essential 
hypertension (401.9) 
-Atrial fibrillation (427.31) 
-Benign essential 
hypertension (401.1) 
-Congestive heart failure, 
unspecified (428.0) 
-SIMVASTATIN 40 MG PO 
TABS 
-NITROGLYCERIN 0.4 MG SL 
SUBL 
-SIMVASTATIN 20 MG PO 
TABS 
-LISINOPRIL 10 MG PO TABS 
-LISINOPRIL 20 MG PO TABS 
-PR ECG AND 
INTERPRETATION 
-EKG 
-STRESS ECHO 
-TTE W/O DOPPLER CMPLT 
-PR CARDIAC STRESS 
COMPLTE 
Dizziness and giddiness 
(780.4) 
-Benign paroxysmal 
positional vertigo (386.11) 
-Other malaise and fatigue 
(780.79) 
-Unspecified hearing loss 
(389.9) 
-Chest pain, unspecified 
(786.50) 
-LORAZEPAM 0.5 MG PO 
TABS 
-MECLIZINE HCL 25 MG PO 
TABS 
-FLUTICASONE 
PROPIONATE 50 MCG/ACT 
NA SUSP 
-PR ECG AND 
INTERPRETATION 
-PR TYMPANOMETRY 
(IMPEDANCE TESTING) 
-EKG 
-PR COMPREHENSIVE 
HEARING TEST 
-ENT, INT 
Impacted cerumen (380.4) -Unspecified hearing loss 
(389.9) 
-Infective otitis externa, 
-NEOMYCIN-POLYMYXIN-
HC 1 % OT SOLN 
-AMOXICILLIN 500 MG PO 
-PR REMVL EAR WAX 
UNI/BILAT (380.4) 
-ENT, INT 
unspecified (380.10) 
-Dysfunction of Eustachian 
tube (381.81) 
-Dizziness and giddiness 
(780.4) 
CAPS 
-FLONASE 50 MCG/ACT NA 
SUSP 
-FLUTICASONE 
PROPIONATE 50 MCG/ACT 
NA SUSP 
-PR COMPREHENSIVE 
HEARING TEST 
-PR TYMPANOMETRY 
(IMPEDANCE TESTING) 
-CERUMEN RMVL BY 
NURSE/MA (NO BILL) 
Other chronic dermatitis 
due to solar radiation 
(692.74) 
-Personal history of other 
malignant neoplasm of skin 
(V10.83) 
-Other seborrheic keratosis 
(702.19) 
-Benign neoplasm of other 
specified sites of skin 
(216.8) 
-Inflamed seborrheic 
keratosis (702.11) 
-TRIAMCINOLONE 
ACETONIDE 0.1 % EX CREA 
-FLUOCINONIDE 0.05 % EX 
CREA 
-PR DESTR PRE-MALIG 
LESN 1ST 
-PR DESTR PRE-MALIG 
LESN 2-14 
-PR BIOPSY OF 
SKIN/SQ/MUC MEMBR 
LESN SINGLE 
-PR DESTRUCT BENIGN 
LESION UP TO 14 LESIONS 
(LIQUID NITROGEN) 
-PR OV EST PT LEV 3 
Chronic kidney disease, 
Stage III (moderate) 
(585.3) 
-Anemia, unspecified 
(285.9) 
-Diabetes with renal 
manifestations, type II or 
unspecified type, not stated 
as uncontrolled (250.40) 
-Proteinuria (791.0) 
-Unspecified essential 
hypertension (401.9) 
-AMLODIPINE BESYLATE 10 
MG PO TABS 
-FUROSEMIDE 20 MG PO 
TABS 
-AMLODIPINE BESYLATE 5 
MG PO TABS 
-LISINOPRIL 40 MG PO TABS 
-HYDROCHLOROTHIAZIDE 
25 MG PO TABS 
-PR PROTHROMBIN TIME 
-PR TX/ PROPHY/ DX INJ 
SQ/ IM 
-PR OV EST PT MIN SERV 
-EKG 
-DEBRIDEMENT OF NAILS, 
6 OR MORE 
Gout, unspecified (274.9) -Unspecified essential 
hypertension (401.9) 
-Other and unspecified 
hyperlipidemia (272.4) 
-Long-term (current) use of 
other medications (V58.69) 
-Screening for malignant 
neoplasms of prostate 
(V76.44) 
-COLCHICINE 0.6 MG PO 
TABS 
-ALLOPURINOL 100 MG PO 
TABS 
-ALLOPURINOL 300 MG PO 
TABS 
-INDOMETHACIN 50 MG PO 
CAPS 
-ATENOLOL 50 MG PO TABS 
-DEBRIDEMENT OF NAILS, 
6 OR MORE 
-TRIAMCINOLONE 
ACETONIDE *KENALOG 
INJ 
Other specified diseases of 
nail (703.8) 
-Keratoderma, acquired 
(701.1) 
-Peripheral vascular 
disease, unspecified (443.9) 
-Ingrowing nail (703.0) 
-Diabetes with neurological 
manifestations, type II or 
unspecified type, not stated 
as uncontrolled (250.60) 
-ECONAZOLE NITRATE 1 % 
EX CREA 
-DEBRIDEMENT OF NAILS, 
6 OR MORE 
-TRIM SKIN LESIONS, 2 TO 
4 
-PARE CORN/CALLUS, 
SINGLE LESION 
-PODIATRY, INT 
-PR DESTR PRE-MALIG 
LESN 1ST 
Preglaucoma, unspecified 
(365.00) 
-Tear film insufficiency, 
unspecified (375.15) 
-Glaucomatous atrophy 
[cupping] of optic disc 
(377.14) 
-Vitreous degeneration 
(379.21) 
-Lens replaced by other 
means (V43.1) 
-GLASSES -PR VISUAL FIELD EXAM 
EXTENDED 
-PR FUNDAL 
PHOTOGRAPHY 
-PR OPHTHALMIC DX 
IMAGING 
-PR VISUAL FIELD EXAM 
LIMITED 
-PR CMPTR OPHTH IMG 
OPTIC NERVE 
Pre-operative examination, 
unspecified (V72.84) 
-Pre-operative 
cardiovascular examination 
(V72.81) 
-Other specified pre-
operative examination 
(V72.83) 
-Unspecified aftercare 
(V58.9) 
-Senile cataract, 
unspecified (366.10) 
-HYDROCODONE-
ACETAMINOPHEN 5-500 MG 
PO TABS 
-VICODIN 5-500 MG PO TABS 
-IBUPROFEN 600 MG PO 
TABS 
-PR ECG AND 
INTERPRETATION 
-EKG 
-CHEST PA & LATERAL 
-PR OV EST PT LEV 3 
-ECG AND 
INTERPRETATION 
(ORDERS ONLY) SZ 
Cough (786.2) -Acute upper respiratory 
infections of unspecified 
site (465.9) 
-Bronchitis, not specified as 
acute or chronic (490) 
-AZITHROMYCIN 250 MG PO 
TABS 
-PROMETHAZINE-CODEINE 
6.25-10 MG/5ML PO SYRP 
-ALBUTEROL SULFATE HFA 
-CHEST PA & LATERAL 
-XR CHEST 2 VIEWS PA 
LATERAL 
-PULSE OXIMETRY SINGLE 
-SERV PROV DURING REG 
-Asthma, unspecified type, 
unspecified (493.90) 
-Acute sinusitis, 
unspecified (461.9) 
108 (90 BASE) MCG/ACT IN 
AERS 
-FLUTICASONE 
PROPIONATE 50 MCG/ACT 
NA SUSP 
-GUAIFENESIN-CODEINE 
100-10 MG/5ML PO SYRP 
SCHED EVE/WKEND/HOL 
HRS 
-PR ECG AND 
INTERPRETATION 
Palpitations (785.1) -Cardiac dysrhythmia, 
unspecified (427.9) 
-Syncope and collapse 
(780.2) 
-Dizziness and giddiness 
(780.4) 
-Shortness of breath 
(786.05) 
-ATENOLOL 25 MG PO TABS 
-METOPROLOL SUCCINATE 
ER 25 MG PO TB24 
-LORAZEPAM 0.5 MG PO 
TABS 
-HOLTER 24 HR ECG 
-PR ECG AND 
INTERPRETATION 
-PR CARDIAC STRESS 
COMPLTE 
-EKG 
-TTE W/O DOPPLER CMPLT 
Need for prophylactic 
vaccination and inoculation 
against influenza (V04.81) 
-Other and unspecified 
hyperlipidemia (272.4) 
-Need for prophylactic 
vaccination and inoculation 
against diphtheria-tetanus-
pertussis, combined [DTP] 
[DTaP] (V06.1) 
-Unspecified essential 
hypertension (401.9) 
-Screening for unspecified 
condition (V82.9) 
-AZITHROMYCIN 250 MG PO 
TABS 
-FLUTICASONE 
PROPIONATE 50 MCG/ACT 
NA SUSP 
-SIMVASTATIN 20 MG PO 
TABS 
-HYDROCHLOROTHIAZIDE 
25 MG PO TABS 
-PR INFLUENZA VACC 
PRES FREE 3+ YO 0.5ML IM 
-INFLUENZA VAC 3+YR 
(V04.81) IM 
-INFLUENZA VAC (FLU 
CLINIC ONLY) 3+YO PA 
-IMMUN ADMIN 
IM/SQ/ID/PERC 1ST VAC 
ONLY 
-TDAP VAC 11-64 YO 
*ADACEL (V06.8) IM 
Benign essential 
hypertension (401.1) 
-Unspecified essential 
hypertension (401.9) 
-Pure hypercholesterolemia 
(272.0) 
-Mixed hyperlipidemia 
(272.2) 
-Diabetes mellitus without 
mention of complication, 
type II or unspecified type, 
not stated as uncontrolled 
(250.00) 
-HYDROCHLOROTHIAZIDE 
25 MG PO TABS 
-ATENOLOL 50 MG PO TABS 
-LISINOPRIL 10 MG PO TABS 
-LISINOPRIL 40 MG PO TABS 
-LISINOPRIL 20 MG PO TABS 
-PR ECG AND 
INTERPRETATION 
-INFLUENZA VAC 3+YR 
(V04.81) IM 
-IMMUN ADMIN 
IM/SQ/ID/PERC 1ST VAC 
ONLY 
-GI, INT 
-PR OV EST PT LEV 3 
Unspecified essential 
hypertension (401.9) 
-Diabetes mellitus without 
mention of complication, 
type II or unspecified type, 
not stated as uncontrolled 
(250.00) 
-Benign essential 
hypertension (401.1) 
-Coronary atherosclerosis 
of unspecified type of 
vessel, native or graft 
(414.00) 
-Obesity, unspecified 
(278.00) 
-HYDROCHLOROTHIAZIDE 
25 MG PO TABS 
-LISINOPRIL 10 MG PO TABS 
-ATENOLOL 50 MG PO TABS 
-LISINOPRIL 20 MG PO TABS 
-SIMVASTATIN 20 MG PO 
TABS 
-PR ECG AND 
INTERPRETATION 
-EKG 
-INFLUENZA VAC 3+YR 
(V04.81) IM 
-IMMUN ADMIN 
IM/SQ/ID/PERC 1ST VAC 
ONLY 
Other screening 
mammogram (V76.12) 
-Screening for malignant 
neoplasms of cervix 
(V76.2) 
-Routine general medical 
examination at a health care 
facility (V70.0) 
-Screening for unspecified 
condition (V82.9) 
-Special screening for 
malignant neoplasms of 
colon (V76.51) 
-FLUTICASONE 
PROPIONATE 50 MCG/ACT 
NA SUSP 
-MAMMO SCREENING 
BILATERAL DIGITAL 
-MAMMOGRAM 
SCREENING 
-GYN CYTOLOGY (PAP) PA 
-OBTAINING SCREEN PAP 
SMEAR 
-PR OV EST PT LEV 3 
Elevated blood pressure 
reading without diagnosis 
of hypertension (796.2) 
-Screening for unspecified 
condition (V82.9) 
-Impaired fasting glucose 
(790.21) 
-Family history of ischemic 
heart disease (V17.3) 
-Obesity, unspecified 
(278.00) 
-AZITHROMYCIN 250 MG PO 
TABS 
-PR OV EST PT LEV 3 
-PR OV EST PT LEV 2 
-CHART ABSTRACTION 
SIMP (V70.3) 
-PR ECG AND 
INTERPRETATION 
-TD VAC 7+ YO (V06.5) IM 
Symptomatic menopausal 
or female climacteric states 
(627.2) 
-Other screening 
mammogram (V76.12) 
-Routine gynecological 
examination (V72.31) 
-Screening for malignant 
neoplasms of cervix 
(V76.2) 
-Disorder of bone and 
cartilage, unspecified 
(733.90) 
-ZOLPIDEM TARTRATE 10 
MG PO TABS 
-MAMMOGRAM 
SCREENING 
-MAMMO SCREENING 
BILATERAL DIGITAL 
-GYN CYTOLOGY (PAP) PA 
-PR OV EST PT LEV 3 
-OBTAINING SCREEN PAP 
SMEAR 
Congestive heart failure, 
unspecified (428.0) 
-Edema (782.3) 
-Coronary atherosclerosis 
of unspecified type of 
vessel, native or graft 
(414.00) 
-Aortic valve disorders 
(424.1) 
-Mitral valve disorders 
(424.0) 
-FUROSEMIDE 20 MG PO 
TABS 
-FUROSEMIDE 40 MG PO 
TABS 
-LASIX 20 MG PO TABS 
-LASIX 40 MG PO TABS 
-LISINOPRIL 5 MG PO TABS 
-TTE W/O DOPPLER CMPLT 
-PR OV EST PT MIN SERV 
-TRANSTHORACIC 
COMPLETE, ECHO 
-CHEST PA & LATERAL 
-PR PROTHROMBIN TIME 
Other and unspecified 
hyperlipidemia (272.4) 
-Diabetes mellitus without 
mention of complication, 
type II or unspecified type, 
not stated as uncontrolled 
(250.00) 
-Benign essential 
hypertension (401.1) 
-Coronary atherosclerosis 
of unspecified type of 
vessel, native or graft 
(414.00) 
-Need for prophylactic 
vaccination and inoculation 
against influenza (V04.81) 
-SIMVASTATIN 20 MG PO 
TABS 
-SIMVASTATIN 40 MG PO 
TABS 
-HYDROCHLOROTHIAZIDE 
25 MG PO TABS 
-LISINOPRIL 10 MG PO TABS 
-LIPITOR 10 MG PO TABS 
-PR ECG AND 
INTERPRETATION 
-IMMUN ADMIN 
IM/SQ/ID/PERC 1ST VAC 
ONLY 
-PR OV EST PT LEV 3 
-INFLUENZA VAC 3+YR 
(V04.81) IM 
-PR INFLUENZA VACC 
PRES FREE 3+ YO 0.5ML IM 
Pure hypercholesterolemia 
(272.0) 
-Benign essential 
hypertension (401.1) 
-Other and unspecified 
hyperlipidemia (272.4) 
-Impaired fasting glucose 
(790.21) 
-Diabetes mellitus without 
mention of complication, 
type II or unspecified type, 
uncontrolled (250.02) 
-SIMVASTATIN 20 MG PO 
TABS 
-SIMVASTATIN 40 MG PO 
TABS 
-LISINOPRIL 10 MG PO TABS 
-ATENOLOL 50 MG PO TABS 
-HYDROCHLOROTHIAZIDE 
25 MG PO TABS 
-EKG 
-PR ECG AND 
INTERPRETATION 
-TDAP VAC 11-64 YO 
*ADACEL (V06.8) IM 
-MAMMO SCREENING 
BILATERAL DIGITAL 
Mixed hyperlipidemia 
(272.2) 
-Benign essential 
hypertension (401.1) 
-Diabetes mellitus without 
mention of complication, 
type II or unspecified type, 
uncontrolled (250.02) 
-Impaired fasting glucose 
(790.21) 
-Obesity, unspecified 
(278.00) 
-SIMVASTATIN 40 MG PO 
TABS 
-SIMVASTATIN 20 MG PO 
TABS 
-LISINOPRIL 10 MG PO TABS 
-SIMVASTATIN 10 MG PO 
TABS 
-METFORMIN HCL 500 MG 
PO TABS 
-TDAP VAC 11-64 YO 
*ADACEL (V06.8) IM 
-INFLUENZA VAC 3+YR 
(V04.81) IM 
-EKG 
-PR CARDIAC STRESS 
COMPLTE 
Unspecified acquired 
hypothyroidism (244.9) 
-Unspecified essential 
hypertension (401.9) 
-Benign essential 
hypertension (401.1) 
-Other screening 
mammogram (V76.12) 
-Other malaise and fatigue 
(780.79) 
-LEVOTHYROXINE SODIUM 
75 MCG PO TABS 
-HYDROCHLOROTHIAZIDE 
25 MG PO TABS 
-LEVOTHYROXINE SODIUM 
100 MCG PO TABS 
-SIMVASTATIN 20 MG PO 
TABS 
-SIMVASTATIN 40 MG PO 
TABS 
-MAMMO SCREENING 
BILATERAL DIGITAL 
-IMMUN ADMIN 
IM/SQ/ID/PERC 1ST VAC 
ONLY 
-PR OV EST PT LEV 3 
-MAMMOGRAM 
SCREENING 
-PR INFLUENZA VACC 
PRES FREE 3+ YO 0.5ML IM 
Depressive disorder, not 
elsewhere classified (311) 
-Insomnia, unspecified 
(780.52) 
-Other malaise and fatigue 
(780.79) 
-Unspecified essential 
hypertension (401.9) 
-ZOLPIDEM TARTRATE 10 
MG PO TABS 
-LORAZEPAM 0.5 MG PO 
TABS 
-HYDROCHLOROTHIAZIDE 
25 MG PO TABS 
-TRAZODONE HCL 50 MG PO 
-IMMUN ADMIN 
IM/SQ/ID/PERC 1ST VAC 
ONLY 
-PR OV EST PT LEV 3 
-INFLUENZA VAC 3+YR 
(V04.81) IM 
-Other and unspecified 
hyperlipidemia (272.4) 
TABS 
-HYDROCODONE-
ACETAMINOPHEN 5-500 MG 
PO TABS 
-MAMMO SCREENING 
BILATERAL DIGITAL 
Personal history of other 
malignant neoplasm of skin 
(V10.83) 
-Other chronic dermatitis 
due to solar radiation 
(692.74) 
-Benign neoplasm of other 
specified sites of skin 
(216.8) 
-Other seborrheic keratosis 
(702.19) 
-Neoplasm of uncertain 
behavior of skin (238.2) 
-FLUOCINONIDE 0.05 % EX 
CREA 
-TRIAMCINOLONE 
ACETONIDE 0.1 % EX CREA 
-PR DESTR PRE-MALIG 
LESN 1ST 
-PR DESTR PRE-MALIG 
LESN 2-14 
-PR BIOPSY OF 
SKIN/SQ/MUC MEMBR 
LESN SINGLE 
-SURGICAL PATHOLOGY 
PA 
-PR OV EST PT LEV 3 
Bronchitis, not specified as 
acute or chronic (490) 
-Acute upper respiratory 
infections of unspecified 
site (465.9) 
-Cough (786.2) 
-Acute sinusitis, 
unspecified (461.9) 
-Acute nasopharyngitis 
[common cold] (460) 
-PROMETHAZINE-CODEINE 
6.25-10 MG/5ML PO SYRP 
-AZITHROMYCIN 250 MG PO 
TABS 
-ZITHROMAX Z-PAK 250 MG 
PO TABS 
-ALBUTEROL 90 MCG/ACT 
IN AERS 
-ALBUTEROL SULFATE HFA 
108 MCG/ACT IN AERS 
-PULSE OXIMETRY SINGLE 
-CHEST PA & LATERAL 
-PR INHALATION RX FOR 
OBSTRUCTION MDI/NEB 
-SERV PROV DURING REG 
SCHED EVE/WKEND/HOL 
HRS 
-XR CHEST 2 VIEWS PA 
LATERAL 
Obstructive sleep apnea 
(adult)(pediatric) (327.23) 
-Sleep disturbance, 
unspecified (780.50) 
-Obesity, unspecified 
(278.00) 
-Other respiratory 
abnormalities (786.09) 
-Other malaise and fatigue 
(780.79) 
-ZOLPIDEM TARTRATE 10 
MG PO TABS 
-FLUTICASONE 
PROPIONATE 50 MCG/ACT 
NA SUSP 
-SIMVASTATIN 20 MG PO 
TABS 
-ZOLPIDEM TARTRATE 5 
MG PO TABS 
-AZITHROMYCIN 250 MG PO 
TABS 
-REFERRAL TO SLEEP 
DISORDERS, INT 
-PR POLYSOMNOGRAPHY 
4 OR MORE 
-PR POLYSOMNOGRAPHY 
W/C P 
-SLEEP STUDY ATTENDED 
-CPAP EQUIPMENT DME 
Anemia, unspecified 
(285.9) 
-Chronic kidney disease, 
Stage III (moderate) 
(585.3) 
-Edema (782.3) 
-Unspecified essential 
hypertension (401.9) 
-Iron deficiency anemia, 
unspecified (280.9) 
-HYDROCHLOROTHIAZIDE 
25 MG PO TABS 
-INFLUENZA VAC 3+YR 
(V04.81) IM 
-PR ECG AND 
INTERPRETATION 
-GI, INT 
-EKG 
-CHEST PA & LATERAL 
Lens replaced by other 
means (V43.1) 
-Tear film insufficiency, 
unspecified (375.15) 
-Vitreous degeneration 
(379.21) 
-Regular astigmatism 
(367.21) 
-Other specified aftercare 
following surgery (V58.49) 
-GLASSES -PR VISUAL FIELD EXAM 
EXTENDED 
-PR REFRACTION 
-PR OPHTHALMIC DX 
IMAGING 
-DIABETIC EYE EXAM (NO 
BILL) 
-PR DIABETIC EYE EXAM 
(NO BILL) 
Chest pain, unspecified 
(786.50) 
-Palpitations (785.1) 
-Other chest pain (786.59) 
-Other respiratory 
abnormalities (786.09) 
-Other malaise and fatigue 
(780.79) 
-AZITHROMYCIN 250 MG PO 
TABS 
-NITROGLYCERIN 0.4 MG SL 
SUBL 
-HYDROCODONE-
ACETAMINOPHEN 5-500 MG 
PO TABS 
-OMEPRAZOLE 20 MG PO 
CPDR 
-PR ECG AND 
INTERPRETATION 
-PR CARDIAC STRESS 
COMPLTE 
-EKG 
-STRESS ECHO 
-CHEST PA & LATERAL 
Acute sinusitis, unspecified 
(461.9) 
-Cough (786.2) 
-Bronchitis, not specified as 
acute or chronic (490) 
-Allergic rhinitis, cause 
unspecified (477.9) 
-Acute pharyngitis (462) 
-AMOXICILLIN 500 MG PO 
CAPS 
-AZITHROMYCIN 250 MG PO 
TABS 
-FLONASE 50 MCG/ACT NA 
SUSP 
-PROMETHAZINE-CODEINE 
6.25-10 MG/5ML PO SYRP 
-PULSE OXIMETRY SINGLE 
-SERV PROV DURING REG 
SCHED EVE/WKEND/HOL 
HRS 
-CHEST PA & LATERAL 
-IMMUN ADMIN 
IM/SQ/ID/PERC 1ST VAC 
-FLUTICASONE 
PROPIONATE 50 MCG/ACT 
NA SUSP 
ONLY 
-ENT, INT 
Atrial fibrillation (427.31) -Encounter for therapeutic 
drug monitoring (V58.83) 
-Coronary atherosclerosis 
of unspecified type of 
vessel, native or graft 
(414.00) 
-Congestive heart failure, 
unspecified (428.0) 
-Unspecified essential 
hypertension (401.9) 
-WARFARIN SODIUM 5 MG 
PO TABS 
-ATENOLOL 50 MG PO TABS 
-ATENOLOL 25 MG PO TABS 
-METOPROLOL SUCCINATE 
ER 50 MG PO TB24 
-SIMVASTATIN 40 MG PO 
TABS 
-PR OV EST PT MIN SERV 
-PR PROTHROMBIN TIME 
-EKG 
-PR ECG AND 
INTERPRETATION 
-TTE W/O DOPPLER CMPLT 
Urinary tract infection, site 
not specified (599.0) 
-Dysuria (788.1) 
-Urinary frequency 
(788.41) 
-Other malaise and fatigue 
(780.79) 
-Vaginitis and 
vulvovaginitis, unspecified 
(616.10) 
-NITROFURANTOIN 
MONOHYD MACRO 100 MG 
PO CAPS 
-CIPROFLOXACIN HCL 250 
MG PO TABS 
-SULFAMETHOXAZOLE-
TMP DS 800-160 MG PO 
TABS 
-MACROBID 100 MG PO 
CAPS 
-CIPRO 500 MG PO TABS 
-SERV PROV DURING REG 
SCHED EVE/WKEND/HOL 
HRS 
-PR URINALYSIS AUTO 
W/O SCOPE 
-PR ECG AND 
INTERPRETATION 
-CYSTOURETHROSCOPY 
-PR URINALYSIS DIP W/O 
SCOPE 
Pain in joint, shoulder 
region (719.41) 
-Other affections of 
shoulder region, not 
elsewhere classified (726.2) 
-Rotator cuff (capsule) 
sprain (840.4) 
-Cervicalgia (723.1) 
-Pain in joint, lower leg 
(719.46) 
-HYDROCODONE-
ACETAMINOPHEN 5-500 MG 
PO TABS 
-VICODIN 5-500 MG PO TABS 
-NAPROXEN 500 MG PO 
TABS 
-SHOULDER 2+ VIEWS 
-ASP/INJ MAJOR 
JOINT/BURS/CYST 
-TRIAMCINOLONE 
ACETONIDE *KENALOG 
INJ 
-UPPER EXTREM JOINT 
MRI 
-PR THERAPEUTIC 
EXERCISES 
Encounter for therapeutic 
drug monitoring (V58.83) 
-Atrial fibrillation (427.31) 
-Congestive heart failure, 
unspecified (428.0) 
-Coronary atherosclerosis 
of unspecified type of 
vessel, native or graft 
(414.00) 
-WARFARIN SODIUM 5 MG 
PO TABS 
-COUMADIN 5 MG PO TABS 
-WARFARIN SODIUM 2.5 MG 
PO TABS 
-ATENOLOL 50 MG PO TABS 
-WARFARIN SODIUM 2 MG 
PO TABS 
-PR OV EST PT MIN SERV 
-PR PROTHROMBIN TIME 
-DEBRIDEMENT OF NAILS, 
6 OR MORE 
-PR DESTR PRE-MALIG 
LESN 2-14 
-PR ECG AND 
INTERPRETATION 
Malignant neoplasm of 
breast (female), unspecified 
(174.9) 
-Lump or mass in breast 
(611.72) 
-Unspecified aftercare 
(V58.9) 
-Disorder of bone and 
cartilage, unspecified 
(733.90) 
-Pre-operative examination, 
unspecified (V72.84) 
-LORAZEPAM 1 MG PO 
TABS 
-LORAZEPAM 0.5 MG PO 
TABS 
-TAMOXIFEN CITRATE 20 
MG PO TABS 
-VICODIN 5-500 MG PO TABS 
-ANASTROZOLE 1 MG PO 
TABS 
-MAMMOGRAM BILAT 
DIAGNOSTIC 
-DEXA BONE DENSITY 
AXIAL SKELETON 
HIPS/PELV/SPINE 
-MAMMO DIAGNOSTIC 
BILATERAL DIGITAL 
-VENIPUNC 
FNGR,HEEL,EAR 
-REFERRAL TO 
ONCOLOGY, INT 
Contact dermatitis and 
other eczema, unspecified 
cause (692.9) 
-Unspecified disorder of 
skin and subcutaneous 
tissue (709.9) 
-Other atopic dermatitis 
and related conditions 
(691.8) 
-Other seborrheic keratosis 
(702.19) 
-Other chronic dermatitis 
due to solar radiation 
(692.74) 
-TRIAMCINOLONE 
ACETONIDE 0.1 % EX CREA 
-FLUOCINONIDE 0.05 % EX 
CREA 
-TRIAMCINOLONE 
ACETONIDE 0.1 % EX OINT 
-DESONIDE 0.05 % EX CREA 
-FLUTICASONE 
PROPIONATE 50 MCG/ACT 
NA SUSP 
-DERMATOLOGY, INT 
-PR BIOPSY OF 
SKIN/SQ/MUC MEMBR 
LESN SINGLE 
-PR DESTR PRE-MALIG 
LESN 1ST 
-REFERRAL TO 
DERMATOLOGY, INT 
-PR OV EST PT LEV 3 
Benign neoplasm of colon 
(211.3) 
-Special screening for 
malignant neoplasms of 
colon (V76.51) 
-Diverticulosis of colon 
(without mention of 
-PEG-KCL-NACL-NASULF-
NA ASC-C 100 G PO SOLR 
-MOVIPREP 100 G PO SOLR 
-OMEPRAZOLE 20 MG PO 
CPDR 
-PR COLONOSCOPY 
W/BIOPSY(S) 
-PR COLONOSCOPY 
W/RMVL 
LESN/TUM/POLYP SNARE 
hemorrhage) (562.10) 
-Family history of 
malignant neoplasm of 
gastrointestinal tract 
(V16.0) 
-Hemorrhage of rectum and 
anus (569.3) 
-SIMVASTATIN 20 MG PO 
TABS 
-REFERRAL TO GI, INT 
-GI, INT 
-PR COLONOSCOPY DIAG 
Disorder of bone and 
cartilage, unspecified 
(733.90) 
-Other screening 
mammogram (V76.12) 
-Symptomatic menopausal 
or female climacteric states 
(627.2) 
-Routine general medical 
examination at a health care 
facility (V70.0) 
-Special screening for 
osteoporosis (V82.81) 
-FOSAMAX 70 MG PO TABS -DEXA BONE DENSITY 
AXIAL SKELETON 
HIPS/PELV/SPINE 
-BONE DENSITY (DEXA) 
-MAMMO SCREENING 
BILATERAL DIGITAL 
-DEXA BONE DENSITY 
STUDY 1+ SITES AXIAL 
SKEL (HIP/PELVIS/SPINE) 
-PR OV EST PT LEV 3 
Presbyopia (367.4) -Myopia (367.1) 
-Hypermetropia (367.0) 
-Astigmatism, unspecified 
(367.20) 
-Other specified visual 
disturbances (368.8) 
-GLASSES -PR REFRACTION 
-DIABETIC EYE EXAM (NO 
BILL) 
-PR VISUAL FIELD EXAM 
EXTENDED 
-INFLUENZA VAC (FLU 
CLINIC ONLY) 3+YO PA 
-PR VISUAL FIELD EXAM 
LIMITED 
Screening for lipoid 
disorders (V77.91) 
-Screening for malignant 
neoplasms of cervix 
(V76.2) 
-Routine general medical 
examination at a health care 
facility (V70.0) 
-Routine gynecological 
examination (V72.31) 
-Screening for unspecified 
condition (V82.9) 
-CHART ABSTRACTION 
SIMP (V70.3) 
-PR OV EST PT LEV 2 
-TDAP VAC 11-64 YO 
*ADACEL (V06.8) IM 
-GYN CYTOLOGY (PAP) PA 
-PR OV EST PT LEV 3 
  
Myopia (367.1) -Regular astigmatism 
(367.21) 
-Astigmatism, unspecified 
(367.20) 
-Other specified visual 
disturbances (368.8) 
-Hypermetropia (367.0) 
-GLASSES -PR REFRACTION 
-CONTACT LENS MISC PA 
-INFLUENZA VAC (FLU 
CLINIC ONLY) 3+YO PA 
-PR VISUAL FIELD EXAM 
EXTENDED 
-DIABETIC EYE EXAM (NO 
BILL) 
Acute pharyngitis (462) -Acute sinusitis, 
unspecified (461.9) 
-Acute nasopharyngitis 
[common cold] (460) 
-Bronchitis, not specified as 
acute or chronic (490) 
-Conjunctivitis, unspecified 
(372.30) 
-AZITHROMYCIN 250 MG PO 
TABS 
-AMOXICILLIN 500 MG PO 
CAPS 
-FLONASE 50 MCG/ACT NA 
SUSP 
-PROMETHAZINE-CODEINE 
6.25-10 MG/5ML PO SYRP 
-AUGMENTIN 875-125 MG PO 
TABS 
-PR STREP A RAPID ASSAY 
W/OPTIC 
-SERV PROV DURING REG 
SCHED EVE/WKEND/HOL 
HRS 
-PULSE OXIMETRY SINGLE 
-ENT, INT 
-CHART ABSTRACTION 
SIMP (V70.3) 
Screening for unspecified 
condition (V82.9) 
-Other screening 
mammogram (V76.12) 
-Other general medical 
examination for 
administrative purposes 
(V70.3) 
-Need for prophylactic 
vaccination and inoculation 
against tetanus-diphtheria 
[Td] (DT) (V06.5) 
-Screening for malignant 
neoplasms of cervix 
(V76.2) 
-PR OV EST PT LEV 3 
-PR OV EST PT LEV 2 
-IMMUN ADMIN 
IM/SQ/ID/PERC 1ST VAC 
ONLY 
-MAMMOGRAM SCREENING 
-GYN CYTOLOGY (PAP) PA 
  
Screening for malignant 
neoplasms of cervix 
(V76.2) 
-Other screening 
mammogram (V76.12) 
-Screening for lipoid 
disorders (V77.91) 
-Routine general medical 
examination at a health care 
facility (V70.0) 
-Screening for unspecified 
condition (V82.9) 
-GYN CYTOLOGY (PAP) PA 
-OBTAINING SCREEN PAP 
SMEAR 
-MAMMOGRAM SCREENING 
-PR OV EST PT LEV 3 
-PR OV EST PT LEV 2 
  
Impotence of organic origin 
(607.84) 
-Hypertrophy (benign) of 
prostate without urinary 
obstruction and other lower 
urinary tract symptom 
(LUTS) (600.00) 
-Other and unspecified 
hyperlipidemia (272.4) 
-Hypertrophy (benign) of 
prostate with urinary 
obstruction and other lower 
urinary tract symptoms 
(LUTS) (600.01) 
-Unspecified essential 
hypertension (401.9) 
-VIAGRA 100 MG PO TABS 
-SILDENAFIL CITRATE 100 
MG PO TABS 
-VIAGRA 50 MG PO TABS 
-TADALAFIL 20 MG PO 
TABS 
-SIMVASTATIN 20 MG PO 
TABS 
-PR OV EST PT LEV 3 
-IMMUN ADMIN 
IM/SQ/ID/PERC 1ST VAC 
ONLY 
-PR DESTR PRE-MALIG 
LESN 1ST 
-PR OV EST PT LEV 2 
-INFLUENZA VAC 3+YR 
(V04.81) IM 
Unspecified sinusitis 
(chronic) (473.9) 
-Acute sinusitis, 
unspecified (461.9) 
-Allergic rhinitis, cause 
unspecified (477.9) 
-Dysfunction of Eustachian 
tube (381.81) 
-Headache (784.0) 
-AMOXICILLIN-POT 
CLAVULANATE 875-125 MG 
PO TABS 
-FLUTICASONE 
PROPIONATE 50 MCG/ACT 
NA SUSP 
-MOMETASONE FUROATE 
50 MCG/ACT NA SUSP 
-FLONASE 50 MCG/ACT NA 
SUSP 
-AUGMENTIN 875-125 MG PO 
TABS 
-PR NASAL ENDO DIAG 
-ENT, INT 
-CT MAXILLOFACIAL W/O 
CONTRAST 
-PR LARYNGOSCOPY FLEX 
DIAG 
-REFERRAL TO ENT, INT 
Need for prophylactic 
vaccination and inoculation 
against viral hepatitis 
(V05.3) 
-Other specified counseling 
(V65.49) 
-Need for prophylactic 
vaccination and inoculation 
against other combinations 
of diseases (V06.8) 
-Need for prophylactic 
vaccination and inoculation 
against poliomyelitis 
(V04.0) 
-Need for prophylactic 
vaccination and inoculation 
against tetanus-diphtheria 
[Td] (DT) (V06.5) 
-CIPROFLOXACIN HCL 500 
MG PO TABS 
-MEFLOQUINE HCL 250 MG 
PO TABS 
-HEP A VAC ADULT (V05.3) 
IM 
-IMMUN ADMIN, EACH 
ADD 
-HEP B VAC ADULT (V05.3) 
IM 
-IMMUN ADMIN 
IM/SQ/ID/PERC 1ST VAC 
ONLY 
-TDAP VAC 11-64 YO 
*ADACEL (V06.8) IM 
Senile cataract, unspecified 
(366.10) 
-Presbyopia (367.4) 
-Regular astigmatism 
(367.21) 
-Preglaucoma, unspecified 
(365.00) 
-Tear film insufficiency, 
unspecified (375.15) 
-GLASSES -PR REFRACTION 
-PR VISUAL FIELD EXAM 
EXTENDED 
-DIABETIC EYE EXAM (NO 
BILL) 
-PR VISUAL FIELD EXAM 
LIMITED 
-PR OPHTHALMIC DX 
IMAGING 
Insomnia, unspecified 
(780.52) 
-Depressive disorder, not 
elsewhere classified (311) 
-Other malaise and fatigue 
(780.79) 
-Sleep disturbance, 
unspecified (780.50) 
-Need for prophylactic 
vaccination and inoculation 
against influenza (V04.81) 
-ZOLPIDEM TARTRATE 10 
MG PO TABS 
-AMBIEN 10 MG PO TABS 
-LORAZEPAM 0.5 MG PO 
TABS 
-ZOLPIDEM TARTRATE 5 
MG PO TABS 
-TRAZODONE HCL 50 MG PO 
TABS 
-PR INFLUENZA VACC 
PRES FREE 3+ YO 0.5ML IM 
-MAMMO SCREENING 
BILATERAL DIGITAL 
-PR OV EST PT LEV 3 
-IMMUN ADMIN 
IM/SQ/ID/PERC 1ST VAC 
ONLY 
-TDAP VAC 11-64 YO 
*ADACEL (V06.8) IM 
Osteoarthrosis, localized, 
primary, lower leg (715.16) 
-Osteoarthrosis, localized, 
not specified whether 
-HYDROCODONE-
ACETAMINOPHEN 10-325 
-ASP/INJ MAJOR 
JOINT/BURS/CYST 
primary or secondary, 
lower leg (715.36) 
-Chondromalacia of patella 
(717.7) 
-Pain in joint, pelvic region 
and thigh (719.45) 
-Enthesopathy of hip region 
(726.5) 
MG PO TABS 
-HYDROCODONE-
ACETAMINOPHEN 5-500 MG 
PO TABS 
-TRIAMCINOLONE 
ACETONIDE *KENALOG 
INJ 
-REFERRAL TO 
ORTHOPEDICS, INT 
-KNEE 3 VIEW 
-BETAMETH ACET 3MG & 
NA PHOS 3MG 
*CELESTONE INJ 
Obesity, unspecified 
(278.00) 
-Routine general medical 
examination at a health care 
facility (V70.0) 
-Other and unspecified 
hyperlipidemia (272.4) 
-Unspecified sleep apnea 
(780.57) 
-Unspecified essential 
hypertension (401.9) 
-METFORMIN HCL 500 MG 
PO TABS 
-HYDROCHLOROTHIAZIDE 
25 MG PO TABS 
-PR OV EST PT LEV 3 
-NUTRITION, INT 
-PR ECG AND 
INTERPRETATION 
-IMMUN ADMIN 
IM/SQ/ID/PERC 1ST VAC 
ONLY 
-PR OV EST PT LEV 2 
Screening for malignant 
neoplasms of prostate 
(V76.44) 
-Special screening for 
malignant neoplasms of 
colon (V76.51) 
-Screening for unspecified 
condition (V82.9) 
-Impaired fasting glucose 
(790.21) 
-Impotence of organic 
origin (607.84) 
-SIMVASTATIN 20 MG PO 
TABS 
-IMMUN ADMIN 
IM/SQ/ID/PERC 1ST VAC 
ONLY 
-PR OV EST PT LEV 3 
-PR OV EST PT LEV 2 
-GI, INT 
-TDAP VAC 11-64 YO 
*ADACEL (V06.8) IM 
Unspecified vitamin D 
deficiency (268.9) 
-Laboratory examination 
ordered as part of a routine 
general medical 
examination (V72.62) 
-Other malaise and fatigue 
(780.79) 
-Need for prophylactic 
vaccination and inoculation 
against diphtheria-tetanus-
pertussis, combined [DTP] 
[DTaP] (V06.1) 
-Anemia, unspecified 
(285.9) 
-ERGOCALCIFEROL 50000 
UNITS PO CAPS 
-FLUTICASONE 
PROPIONATE 50 MCG/ACT 
NA SUSP 
-SIMVASTATIN 20 MG PO 
TABS 
-OMEPRAZOLE 20 MG PO 
CPDR 
-ZOLPIDEM TARTRATE 10 
MG PO TABS 
-MAMMO SCREENING 
BILATERAL DIGITAL 
-TDAP VAC 11-64 YO 
*ADACEL (V06.8) IM 
-DEXA BONE DENSITY 
AXIAL SKELETON 
HIPS/PELV/SPINE 
-EKG 
-REFERRAL TO GI, INT 
Lumbago (724.2) -Sciatica (724.3) 
-Cervicalgia (723.1) 
-Thoracic or lumbosacral 
neuritis or radiculitis, 
unspecified (724.4) 
-Degeneration of lumbar or 
lumbosacral intervertebral 
disc (722.52) 
-HYDROCODONE-
ACETAMINOPHEN 5-500 MG 
PO TABS 
-CYCLOBENZAPRINE HCL 
10 MG PO TABS 
-FLEXERIL 10 MG PO TABS 
-VICODIN 5-500 MG PO TABS 
-CARISOPRODOL 350 MG PO 
TABS 
-LS SPINE 2 VIEWS 
-LUMBAR SPINE MRI W/O 
CONTR 
-PHYSICAL MEDICINE, INT 
-PHYSICAL THERAPY, INT 
-PHYSICAL MEDICINE, INT 
Backache, unspecified 
(724.5) 
-Sciatica (724.3) 
-Cervicalgia (723.1) 
-Thoracic or lumbosacral 
neuritis or radiculitis, 
unspecified (724.4) 
-Pain in joint, pelvic region 
and thigh (719.45) 
-HYDROCODONE-
ACETAMINOPHEN 5-500 MG 
PO TABS 
-CYCLOBENZAPRINE HCL 
10 MG PO TABS 
-NAPROXEN 500 MG PO 
TABS 
-FLEXERIL 10 MG PO TABS 
-VICODIN 5-500 MG PO TABS 
-LS SPINE 2 VIEWS 
-PHYSICAL MEDICINE, INT 
-PR ECG AND 
INTERPRETATION 
-LUMBAR SPINE MRI W/O 
CONTR 
-PR OV EST PT LEV 3 
Thoracic or lumbosacral 
neuritis or radiculitis, 
unspecified (724.4) 
-Spinal stenosis, lumbar 
region, without neurogenic 
claudication (724.02) 
-Displacement of lumbar 
intervertebral disc without 
myelopathy (722.10) 
-Sciatica (724.3) 
-Lumbago (724.2) 
-HYDROCODONE-
ACETAMINOPHEN 10-325 
MG PO TABS 
-HYDROCODONE-
ACETAMINOPHEN 5-500 MG 
PO TABS 
-GABAPENTIN 300 MG PO 
CAPS 
-CYCLOBENZAPRINE HCL 
10 MG PO TABS 
-PREDNISONE 20 MG PO 
TABS 
-LUMBAR SPINE MRI W/O 
CONTR 
-MRI LUMBAR SPINE WO 
CONTRAST 
-REFERRAL TO PHYSICAL 
MEDICINE, INT 
-PHYSICAL MEDICINE, INT 
-PHYSICAL MEDICINE, INT 
Inflamed seborrheic 
keratosis (702.11) 
-Other chronic dermatitis 
due to solar radiation 
(692.74) 
-Other dyschromia (709.09) 
-Viral warts, unspecified 
(078.10) 
-Nevus, non-neoplastic 
(448.1) 
-TRIAMCINOLONE 
ACETONIDE 0.1 % EX CREA 
-ECONAZOLE NITRATE 1 % 
EX CREA 
-PR DESTRUCT BENIGN 
LESION UP TO 14 LESIONS 
(LIQUID NITROGEN) 
-PR DESTR PRE-MALIG 
LESN 1ST 
-PR DESTR PRE-MALIG 
LESN 2-14 
-PR BIOPSY OF 
SKIN/SQ/MUC MEMBR 
LESN SINGLE 
-DERMATOLOGY, INT 
Other seborrheic keratosis 
(702.19) 
-Actinic keratosis (702.0) 
-Inflamed seborrheic 
keratosis (702.11) 
-Other dyschromia (709.09) 
-Personal history of other 
malignant neoplasm of skin 
(V10.83) 
-TRIAMCINOLONE 
ACETONIDE 0.1 % EX CREA 
-FLUOCINONIDE 0.05 % EX 
CREA 
-PR DESTR PRE-MALIG 
LESN 1ST 
-PR DESTR PRE-MALIG 
LESN 2-14 
-PR BIOPSY OF 
SKIN/SQ/MUC MEMBR 
LESN SINGLE 
-PR DESTRUCT BENIGN 
LESION UP TO 14 LESIONS 
(LIQUID NITROGEN) 
-PR OV EST PT LEV 3 
Allergic rhinitis due to 
other allergen (477.8) 
-Allergic rhinitis due to 
pollen (477.0) 
-Asthma, unspecified type, 
unspecified (493.90) 
-Extrinsic asthma, 
unspecified (493.00) 
-Acute sinusitis, 
unspecified (461.9) 
-FLUTICASONE 
PROPIONATE 50 MCG/ACT 
NA SUSP 
-FLONASE 50 MCG/ACT NA 
SUSP 
-MOMETASONE FUROATE 
50 MCG/ACT NA SUSP 
-ALLEGRA 180 MG PO TABS 
-NASONEX 50 MCG/ACT NA 
SUSP 
-IMMUNOTHERAPY 
MULTIPLE 
-ANTIGEN ALLERGY MAT 
FOR INJ (06041) PA 
-PR IMMUNOTX W 
EXTRACT 2+ INJ 
-INFLUENZA VAC (FLU 
CLINIC ONLY) 3+YO PA 
-ENT, INT 
Allergic rhinitis, cause 
unspecified (477.9) 
-Acute sinusitis, 
unspecified (461.9) 
-Routine general medical 
examination at a health care 
facility (V70.0) 
-Acute upper respiratory 
infections of unspecified 
site (465.9) 
-Cough (786.2) 
-FLUTICASONE 
PROPIONATE 50 MCG/ACT 
NA SUSP 
-FLONASE 50 MCG/ACT NA 
SUSP 
-MOMETASONE FUROATE 
50 MCG/ACT NA SUSP 
-AZITHROMYCIN 250 MG PO 
TABS 
-NASONEX 50 MCG/ACT NA 
SUSP 
-PR OV EST PT LEV 3 
-IMMUN ADMIN 
IM/SQ/ID/PERC 1ST VAC 
ONLY 
-IMMUNOTHERAPY 
MULTIPLE 
-MAMMOGRAM 
SCREENING 
-INFLUENZA VAC (FLU 
CLINIC ONLY) 3+YO PA 
Abdominal pain, 
unspecified site (789.00) 
-Abdominal pain, epigastric 
(789.06) 
-Abdominal pain, other 
specified site (789.09) 
-Esophageal reflux 
(530.81) 
-Constipation, unspecified 
(564.00) 
-CIPRO 500 MG PO TABS 
-METRONIDAZOLE 500 MG 
PO TABS 
-OMEPRAZOLE 20 MG PO 
CPDR 
-HYDROCODONE-
ACETAMINOPHEN 5-500 MG 
PO TABS 
-ACIPHEX 20 MG PO TBEC 
-US ABDOMEN COMPLETE 
-GI, INT 
-ABDOMEN/PELVIS CT PA 
-PR ECG AND 
INTERPRETATION 
-SERV PROV DURING REG 
SCHED EVE/WKEND/HOL 
HRS 
 (V72.3) -Other general medical 
examination for 
administrative purposes 
(V70.3) 
-Need for prophylactic 
vaccination and inoculation 
against tetanus-diphtheria 
[Td] (DT) (V06.5) 
-Screening for unspecified 
condition (V82.9) 
-Symptomatic menopausal 
or female climacteric states 
(627.2) 
-ALBUTEROL 90 MCG/ACT 
IN AERS 
-GYN CYTOLOGY (PAP) PA 
-MAMMOGRAM 
SCREENING 
-CHART ABSTRACTION 
SIMP (V70.3) 
-PR OV EST PT LEV 2 
-TD VAC 7+ YO (V06.5) IM 
Other specified 
vaccinations against 
streptococcus pneumoniae 
[pneumococcus] (V03.82) 
-Screening for malignant 
neoplasms of prostate 
(V76.44) 
-Routine general medical 
examination at a health care 
-ALBUTEROL SULFATE HFA 
108 (90 BASE) MCG/ACT IN 
AERS 
-PNEUMOCOCCAL VAC 
(V03.82) IM/SQ 
-PNEUMOCOCCAL 
POLYSACC VAC 2+ YO 
(V03.82) IM/SQ 
facility (V70.0) 
-Need for prophylactic 
vaccination and inoculation 
against tetanus-diphtheria 
[Td] (DT) (V06.5) 
-Need for prophylactic 
vaccination and inoculation 
against other specified 
disease (V05.8) 
-IMMUN ADMIN 
IM/SQ/ID/PERC 1ST VAC 
ONLY 
-INFLUENZA VAC 3+YR 
(V04.81) IM 
-TDAP VAC 11-64 YO 
*ADACEL (V06.8) IM 
Other psoriasis (696.1) -Other dyschromia (709.09) 
-Other atopic dermatitis 
and related conditions 
(691.8) 
-Seborrheic dermatitis, 
unspecified (690.10) 
-Unspecified pruritic 
disorder (698.9) 
-CLOBETASOL PROPIONATE 
0.05 % EX OINT 
-CLOBETASOL PROPIONATE 
0.05 % EX CREA 
-FLUOCINONIDE 0.05 % EX 
CREA 
-DESONIDE 0.05 % EX CREA 
-TRIAMCINOLONE 
ACETONIDE 0.1 % EX CREA 
-PR ULTRAVIOLET 
THERAPY 
-DERMATOLOGY, INT 
-PR BIOPSY OF 
SKIN/SQ/MUC MEMBR 
LESN SINGLE 
-PR DESTR PRE-MALIG 
LESN 1ST 
-DERMATOLOGY, INT 
Other general medical 
examination for 
administrative purposes 
(V70.3) 
-Routine general medical 
examination at a health care 
facility (V70.0) 
-Need for prophylactic 
vaccination and inoculation 
against tetanus-diphtheria 
[Td] (DT) (V06.5) 
-Screening for lipoid 
disorders (V77.91) 
-ALBUTEROL 90 MCG/ACT 
IN AERS 
-FLONASE 50 MCG/ACT NA 
SUSP 
-CHART ABSTRACTION 
SIMP (V70.3) 
-CHART ABSTRACTION 
INT (V70.3) 
-PAMFONLINE 
ENROLLMENT 
-MAMMOGRAM 
SCREENING 
-PR CHART ABSTRACTION 
COMP (V70.3) 
Migraine, unspecified, 
without mention of 
intractable migraine 
without mention of status 
migrainosus (346.90) 
-Anxiety state, unspecified 
(300.00) 
-Cervicalgia (723.1) 
-Other screening 
mammogram (V76.12) 
-Myalgia and myositis, 
unspecified (729.1) 
-SUMATRIPTAN SUCCINATE 
50 MG PO TABS 
-HYDROCODONE-
ACETAMINOPHEN 5-500 MG 
PO TABS 
-PROMETHAZINE HCL 25 
MG PO TABS 
-IMITREX 100 MG PO TABS 
-ZOLPIDEM TARTRATE 10 
MG PO TABS 
-MAMMO SCREENING 
BILATERAL DIGITAL 
-GYN CYTOLOGY (PAP) PA 
-PR OV EST PT LEV 3 
-MAMMOGRAM 
SCREENING 
-NEUROLOGY, INT 
Routine general medical 
examination at a health care 
facility (V70.0) 
-Other screening 
mammogram (V76.12) 
-Special screening for 
malignant neoplasms of 
colon (V76.51) 
-Screening for malignant 
neoplasms of prostate 
(V76.44) 
-Need for prophylactic 
vaccination and inoculation 
against diphtheria-tetanus-
pertussis, combined [DTP] 
[DTaP] (V06.1) 
-PR OV EST PT LEV 3 
-PR OV EST PT LEV 2 
-IMMUN ADMIN 
IM/SQ/ID/PERC 1ST VAC 
ONLY 
-TDAP VAC 11-64 YO 
*ADACEL (V06.8) IM 
-GYN CYTOLOGY (PAP) PA 
  
Special screening for 
malignant neoplasms of 
colon (V76.51) 
-Routine general medical 
examination at a health care 
facility (V70.0) 
-Benign neoplasm of colon 
(211.3) 
-Screening for unspecified 
condition (V82.9) 
-Other screening 
mammogram (V76.12) 
-PEG-KCL-NACL-NASULF-
NA ASC-C 100 G PO SOLR 
-GI, INT 
-REFERRAL TO GI, INT 
-PR OV EST PT LEV 3 
-PR OV EST PT LEV 2 
-IMMUN ADMIN 
IM/SQ/ID/PERC 1ST VAC 
ONLY 
Care involving other 
physical therapy (V57.1) 
-Pain in joint, shoulder 
region (719.41) 
-Pain in joint, lower leg 
(719.46) 
-Lumbago (724.2) 
-Pain in joint, pelvic region 
and thigh (719.45) 
-HYDROCODONE-
ACETAMINOPHEN 5-500 MG 
PO TABS 
-HYDROCODONE-
ACETAMINOPHEN 10-325 
MG PO TABS 
-CYCLOBENZAPRINE HCL 
10 MG PO TABS 
-HYDROCODONE-
-PR PHYS THERAPY 
EVALUATION 
-PR THERAPEUTIC 
EXERCISES 
-PR MANUAL THER TECH 
1+REGIONS EA 15 MIN 
-PR ELECTRIC 
STIMULATION THERAPY 
-REFERRAL TO PHYSICAL 
THERAPY, INT 
ACETAMINOPHEN 5-325 MG 
PO TABS 
Rheumatoid arthritis 
(714.0) 
-Unspecified inflammatory 
polyarthropathy (714.9) 
-Arthropathy, unspecified, 
site unspecified (716.90) 
-Sicca syndrome (710.2) 
-FOLIC ACID 1 MG PO TABS 
-METHOTREXATE 2.5 MG PO 
TABS 
-PREDNISONE 5 MG PO 
TABS 
-PREDNISONE 1 MG PO 
TABS 
-HYDROXYCHLOROQUINE 
SULFATE 200 MG PO TABS 
-RHEUMATOLOGY, INT 
-METHYLPRED ACET 
80MG *DEPO-MEDROL INJ 
-TRIAMCINOLONE 
ACETONIDE *KENALOG 
INJ 
-ASP/INJ INT 
JOINT/BURS/CYST 
-PR METHLYPRED ACET 
(BU 21 - 40MG) *DEPO-
MEDROL INJ 
Osteoporosis, unspecified 
(733.00) 
-Unspecified acquired 
hypothyroidism (244.9) 
-Osteoarthrosis, unspecified 
whether generalized or 
localized, site unspecified 
(715.90) 
-Benign essential 
hypertension (401.1) 
-Unspecified essential 
hypertension (401.9) 
-FOSAMAX 70 MG PO TABS 
-ALENDRONATE SODIUM 70 
MG PO TABS 
-HYDROCHLOROTHIAZIDE 
25 MG PO TABS 
-ACTONEL 35 MG PO TABS 
-DEXA BONE DENSITY 
AXIAL SKELETON 
HIPS/PELV/SPINE 
-BONE DENSITY (DEXA) 
-DEXA BONE DENSITY 
STUDY 1+ SITES AXIAL 
SKEL (HIP/PELVIS/SPINE) 
-INFLUENZA VAC 3+YR 
(V04.81) IM 
-MAMMOGRAM 
SCREENING 
Other malaise and fatigue 
(780.79) 
-Routine general medical 
examination at a health care 
facility (V70.0) 
-Dizziness and giddiness 
(780.4) 
-Other respiratory 
abnormalities (786.09) 
-Screening for unspecified 
condition (V82.9) 
-AZITHROMYCIN 250 MG PO 
TABS 
-FLUTICASONE 
PROPIONATE 50 MCG/ACT 
NA SUSP 
-PR ECG AND 
INTERPRETATION 
-CHEST PA & LATERAL 
-PR OV EST PT LEV 3 
-EKG 
-TDAP VAC 11-64 YO 
*ADACEL (V06.8) IM 
Long-term (current) use of 
anticoagulants (V58.61) 
-Atrial fibrillation (427.31) 
-Congestive heart failure, 
unspecified (428.0) 
-Coronary atherosclerosis 
of unspecified type of 
vessel, native or graft 
(414.00) 
-WARFARIN SODIUM 5 MG 
PO TABS 
-COUMADIN 5 MG PO TABS 
-WARFARIN SODIUM 2.5 MG 
PO TABS 
-ATENOLOL 50 MG PO TABS 
-WARFARIN SODIUM 2 MG 
PO TABS 
-PR OV EST PT MIN SERV 
-PR PROTHROMBIN TIME 
-DEBRIDEMENT OF NAILS, 
6 OR MORE 
-PR ECG AND 
INTERPRETATION 
-EKG 
Spinal stenosis, lumbar 
region, without neurogenic 
claudication (724.02) 
-Degeneration of lumbar or 
lumbosacral intervertebral 
disc (722.52) 
-Lumbosacral spondylosis 
without myelopathy (721.3) 
-Displacement of lumbar 
intervertebral disc without 
myelopathy (722.10) 
-Lumbago (724.2) 
-HYDROCODONE-
ACETAMINOPHEN 10-325 
MG PO TABS 
-GABAPENTIN 300 MG PO 
CAPS 
-HYDROCODONE-
ACETAMINOPHEN 5-500 MG 
PO TABS 
-TRAMADOL HCL 50 MG PO 
TABS 
-PREDNISONE 20 MG PO 
TABS 
-LUMBAR SPINE MRI W/O 
CONTR 
-LS SPINE 2 VIEWS 
-PHYSICAL MEDICINE, INT 
-MRI LUMBAR SPINE WO 
CONTRAST 
-PHYSICAL MEDICINE, INT 
Unspecified hemorrhoids 
without mention of 
complication (455.6) 
-Internal hemorrhoids 
without mention of 
complication (455.0) 
-Benign neoplasm of colon 
(211.3) 
-Anal or rectal pain 
(569.42) 
-Personal history of colonic 
polyps (V12.72) 
-HYDROCORTISONE 
ACETATE 25 MG PR SUPP 
-ANUSOL-HC 25 MG PR SUPP 
-HYDROCORTISONE 2.5 % 
PR CREA 
-ANUSOL-HC 2.5 % PR CREA 
-PEG-KCL-NACL-NASULF-
NA ASC-C 100 G PO SOLR 
-ANOSCOPY 
-SURGERY, INT 
-PR COLONOSCOPY 
W/BIOPSY(S) 
-LIGATION OF 
HEMORRHOID(S) 
-GI, INT 
Dermatophytosis of nail 
(110.1) 
-Dermatophytosis of foot 
(110.4) 
-Ingrowing nail (703.0) 
-Keratoderma, acquired 
(701.1) 
-Peripheral vascular 
disease, unspecified (443.9) 
-ECONAZOLE NITRATE 1 % 
EX CREA 
-TERBINAFINE HCL 250 MG 
PO TABS 
-TRIAMCINOLONE 
ACETONIDE 0.1 % EX CREA 
-DEBRIDEMENT OF NAILS, 
6 OR MORE 
-TRIM SKIN LESIONS, 2 TO 
4 
-PARE CORN/CALLUS, 
SINGLE LESION 
-PODIATRY, INT 
-CEPHALEXIN 500 MG PO 
CAPS 
-PR DESTR PRE-MALIG 
LESN 1ST 
Pain in joint, lower leg 
(719.46) 
-Chondromalacia of patella 
(717.7) 
-Tear of medial cartilage or 
meniscus of knee, current 
(836.0) 
-Pain in limb (729.5) 
-Pain in joint, pelvic region 
and thigh (719.45) 
-HYDROCODONE-
ACETAMINOPHEN 5-500 MG 
PO TABS 
-VICODIN 5-500 MG PO TABS 
-IBUPROFEN 600 MG PO 
TABS 
-ASP/INJ MAJOR 
JOINT/BURS/CYST 
-REFERRAL TO 
ORTHOPEDICS, INT 
-TRIAMCINOLONE 
ACETONIDE *KENALOG 
INJ 
-LOWER EXTREMITY 
JOINT MRI W/O CONTR 
-ORTHOPEDICS, INT 
Pain in joint, pelvic region 
and thigh (719.45) 
-Lumbago (724.2) 
-Sciatica (724.3) 
-Backache, unspecified 
(724.5) 
-Pain in joint, lower leg 
(719.46) 
-HYDROCODONE-
ACETAMINOPHEN 5-500 MG 
PO TABS 
-VICODIN 5-500 MG PO TABS 
-PELVIS LIMITED 
-LS SPINE 2 VIEWS 
-XR PELVIS 1 OR 2 VIEWS 
-REFERRAL TO 
ORTHOPEDICS, INT 
-ASP/INJ MAJOR 
JOINT/BURS/CYST 
Anxiety state, unspecified 
(300.00) 
-Insomnia, unspecified 
(780.52) 
-Generalized anxiety 
disorder (300.02) 
-Other malaise and fatigue 
(780.79) 
-Headache (784.0) 
-LORAZEPAM 0.5 MG PO 
TABS 
-ZOLPIDEM TARTRATE 10 
MG PO TABS 
-LORAZEPAM 1 MG PO 
TABS 
-ALPRAZOLAM 0.25 MG PO 
TABS 
-CLONAZEPAM 0.5 MG PO 
TABS 
-MAMMO SCREENING 
BILATERAL DIGITAL 
-EKG 
-PR ECG AND 
INTERPRETATION 
-PR INFLUENZA VACC 
PRES FREE 3+ YO 0.5ML IM 
-TDAP VAC 11-64 YO 
*ADACEL (V06.8) IM 
Generalized anxiety 
disorder (300.02) 
-Depressive disorder, not 
elsewhere classified (311) 
-Insomnia, unspecified 
(780.52) 
-Irritable bowel syndrome 
(564.1) 
-Sleep disturbance, 
unspecified (780.50) 
-LORAZEPAM 0.5 MG PO 
TABS 
-CLONAZEPAM 0.5 MG PO 
TABS 
-TRAZODONE HCL 50 MG PO 
TABS 
-LORAZEPAM 1 MG PO 
TABS 
-AMBIEN 10 MG PO TABS 
-MAMMOGRAM 
SCREENING 
-GI, INT 
-CHART ABSTRACTION 
INT (V70.3) 
Cervicalgia (723.1) -Lumbago (724.2) 
-Backache, unspecified 
(724.5) 
-Headache (784.0) 
-Brachial neuritis or 
radiculitis NOS (723.4) 
-CYCLOBENZAPRINE HCL 
10 MG PO TABS 
-HYDROCODONE-
ACETAMINOPHEN 5-500 MG 
PO TABS 
-FLEXERIL 10 MG PO TABS 
-NAPROXEN 500 MG PO 
TABS 
-CARISOPRODOL 350 MG PO 
TABS 
-PHYSICAL MEDICINE, INT 
-SPINE CERVICAL 
COMPLETE 
-PHYSICAL THERAPY, INT 
-PHYSICAL THERAPY, EXT 
-PR THERAPEUTIC 
EXERCISES 
Impaired fasting glucose 
(790.21) 
-Routine general medical 
examination at a health care 
facility (V70.0) 
-Screening for malignant 
neoplasms of prostate 
(V76.44) 
-Other and unspecified 
hyperlipidemia (272.4) 
-Overweight (278.02) 
-SIMVASTATIN 20 MG PO 
TABS 
-HYDROCHLOROTHIAZIDE 
25 MG PO TABS 
-SIMVASTATIN 40 MG PO 
TABS 
-PR OV EST PT LEV 3 
-TDAP VAC 11-64 YO 
*ADACEL (V06.8) IM 
-PR OV EST PT LEV 2 
-NUTRITION, INT 
-PR INFLUENZA VACC 
PRES FREE 3+ YO 0.5ML IM 
Actinic keratosis (702.0) -Other chronic dermatitis 
due to solar radiation 
(692.74) 
-Other seborrheic keratosis 
(702.19) 
-Benign neoplasm of other 
specified sites of skin 
(216.8) 
-Neoplasm of uncertain 
behavior of skin (238.2) 
-TRIAMCINOLONE 
ACETONIDE 0.1 % EX CREA 
-FLUOCINONIDE 0.05 % EX 
CREA 
-GLASSES 
-PR DESTR PRE-MALIG 
LESN 1ST 
-PR DESTR PRE-MALIG 
LESN 2-14 
-PR BIOPSY OF 
SKIN/SQ/MUC MEMBR 
LESN SINGLE 
-SURGICAL PATHOLOGY 
PA 
-PR OV EST PT LEV 3 
 
 
